WO2001068858A2 - Nouveaux recepteurs couples a la proteine g - Google Patents
Nouveaux recepteurs couples a la proteine g Download PDFInfo
- Publication number
- WO2001068858A2 WO2001068858A2 PCT/US2001/008456 US0108456W WO0168858A2 WO 2001068858 A2 WO2001068858 A2 WO 2001068858A2 US 0108456 W US0108456 W US 0108456W WO 0168858 A2 WO0168858 A2 WO 0168858A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- ngpcr
- nucleic acid
- sequence
- amino acid
- Prior art date
Links
- 102000005962 receptors Human genes 0.000 title description 86
- 108020003175 receptors Proteins 0.000 title description 86
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 title 1
- 102000052301 human GNAZ Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 234
- 238000000034 method Methods 0.000 claims abstract description 229
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 209
- 229920001184 polypeptide Polymers 0.000 claims abstract description 197
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 186
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 309
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 294
- 210000004027 cell Anatomy 0.000 claims description 264
- 241000282414 Homo sapiens Species 0.000 claims description 254
- 150000001875 compounds Chemical class 0.000 claims description 191
- 230000027455 binding Effects 0.000 claims description 167
- 150000007523 nucleic acids Chemical class 0.000 claims description 139
- 102000039446 nucleic acids Human genes 0.000 claims description 129
- 108020004707 nucleic acids Proteins 0.000 claims description 129
- 102000004169 proteins and genes Human genes 0.000 claims description 126
- 230000000694 effects Effects 0.000 claims description 108
- 230000014509 gene expression Effects 0.000 claims description 108
- 102000040430 polynucleotide Human genes 0.000 claims description 108
- 108091033319 polynucleotide Proteins 0.000 claims description 108
- 239000002157 polynucleotide Substances 0.000 claims description 108
- 238000003556 assay Methods 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 96
- 108020004414 DNA Proteins 0.000 claims description 92
- 239000002773 nucleotide Substances 0.000 claims description 87
- 125000003729 nucleotide group Chemical group 0.000 claims description 86
- 239000000523 sample Substances 0.000 claims description 62
- 238000009396 hybridization Methods 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 51
- 239000013598 vector Substances 0.000 claims description 51
- 208000020016 psychiatric disease Diseases 0.000 claims description 46
- 108091006027 G proteins Proteins 0.000 claims description 44
- 102000030782 GTP binding Human genes 0.000 claims description 44
- 108091000058 GTP-Binding Proteins 0.000 claims description 44
- 238000003752 polymerase chain reaction Methods 0.000 claims description 40
- 239000013604 expression vector Substances 0.000 claims description 39
- 238000012216 screening Methods 0.000 claims description 39
- 210000004556 brain Anatomy 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 29
- 230000000295 complement effect Effects 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 28
- 238000012163 sequencing technique Methods 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 230000004071 biological effect Effects 0.000 claims description 23
- 230000003993 interaction Effects 0.000 claims description 22
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 20
- 108091026890 Coding region Proteins 0.000 claims description 18
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 241000701447 unidentified baculovirus Species 0.000 claims description 15
- 108700028369 Alleles Proteins 0.000 claims description 14
- 241000238631 Hexapoda Species 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 11
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 9
- 238000000159 protein binding assay Methods 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 238000010396 two-hybrid screening Methods 0.000 claims description 8
- 108090000189 Neuropeptides Proteins 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 5
- 229960000633 dextran sulfate Drugs 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 102000003797 Neuropeptides Human genes 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 238000010232 migration assay Methods 0.000 claims description 3
- 230000005257 nucleotidylation Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 2
- 102000003505 Myosin Human genes 0.000 claims description 2
- 108060008487 Myosin Proteins 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000714474 Rous sarcoma virus Species 0.000 claims description 2
- 241000710961 Semliki Forest virus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 238000000975 co-precipitation Methods 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 238000001400 expression cloning Methods 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000256251 Spodoptera frugiperda Species 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract description 91
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract description 86
- 239000003446 ligand Substances 0.000 description 65
- 239000012634 fragment Substances 0.000 description 62
- 210000001519 tissue Anatomy 0.000 description 48
- 208000035475 disorder Diseases 0.000 description 42
- 239000000556 agonist Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 31
- 239000013615 primer Substances 0.000 description 30
- 230000004913 activation Effects 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 239000000126 substance Substances 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 24
- 239000012528 membrane Substances 0.000 description 24
- 230000003834 intracellular effect Effects 0.000 description 20
- 230000002159 abnormal effect Effects 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 230000004927 fusion Effects 0.000 description 18
- 238000013537 high throughput screening Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 239000011575 calcium Substances 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 15
- 229910052791 calcium Inorganic materials 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 108700008625 Reporter Genes Proteins 0.000 description 11
- 239000002858 neurotransmitter agent Substances 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 10
- 208000020925 Bipolar disease Diseases 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 230000001594 aberrant effect Effects 0.000 description 8
- 230000036506 anxiety Effects 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 102000003790 Thrombin receptors Human genes 0.000 description 7
- 108090000166 Thrombin receptors Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 208000016285 Movement disease Diseases 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 101710185494 Zinc finger protein Proteins 0.000 description 6
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- -1 antibodies Substances 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000006539 extracellular acidification Effects 0.000 description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 206010012218 Delirium Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000036623 Severe mental retardation Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010000239 Aequorin Proteins 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010028665 Myxoedema Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 206010036049 Polycystic ovaries Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010048327 Supranuclear palsy Diseases 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000013262 cAMP assay Methods 0.000 description 3
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000010001 cellular homeostasis Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108091000126 Dihydroorotase Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 101710136524 X polypeptide Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000012637 allosteric effector Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001159 caudate nucleus Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-UHFFFAOYSA-N icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(O)=O YZXBAPSDXZZRGB-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 210000002975 pon Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- MXQCHKYVLFWFJG-AFJQEWLFSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](CC=1NC=NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1NCCC1)C(C)C)C(C)C)C1=CC=CC=C1 MXQCHKYVLFWFJG-AFJQEWLFSA-N 0.000 description 1
- INAPMGSXUVUWAF-PTQMNWPWSA-N 1D-myo-inositol 3-phosphate Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1O INAPMGSXUVUWAF-PTQMNWPWSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000030907 Aspartate Carbamoyltransferase Human genes 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101150019620 CAD gene Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710113083 Carbamoyl-phosphate synthase Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000000532 Chronic Brain Injury Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102100034581 Dihydroorotase Human genes 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101100001670 Emericella variicolor andE gene Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101800002395 GLGPRPLRF-amide Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 101100001708 Mus musculus Angptl4 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108010036758 SchistoFLRFamide Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003348 filter assay Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002263 peptidergic effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229930001118 polyketide hybrid Natural products 0.000 description 1
- 125000003308 polyketide hybrid group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Definitions
- the present invention relates generally to the fields of genetics and cellular and molecular biology. More particularly, the invention relates to novel G protein coupled receptors, to polynucleotides that encode such novel receptors, to reagents such as antibodies, probes, primers and kits comprising such antibodies, probes, primers related to thesame, and to methods which use the novel G protein coupled receptors, polynucleotides or reagents.
- GPCRs G protein-coupled receptors
- 7TM seven transmembrane
- These seven transmembrane domains define three extracellular loops and three intracellular loops, in addition to the amino- and carboxy- terminal domains.
- the extracellular portions of the receptor have a role in recognizing and binding one or more extracellular binding partners (e.g., ligands), whereas the intracellular portions have a role in recognizing and communicating with downstream molecules in the signal transduction cascade.
- the G protein-coupled receptors bind a variety of ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and even photons, and are important in the normal (and sometimes the aberrant) function of many cell types.
- ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and even photons.
- G protein guanine-nucleotide-binding regulatory protein
- the G protein transmits a signal to an effector molecule within the cell, by either stimulating or inhibiting the activity of that effector molecule.
- effector molecules include adenylate cyclase, phospholipases and ion channels.
- Adenylate cyclase and phospholipases are enzymes that are involved in the production of the second messenger molecules cAMP, inositol triphosphate and diacyglycerol. It is through this sequence of events that an extracellular ligand stimuli exerts intracellular changes through a G protein-coupled receptor.
- Each such receptor has its own characteristic primary structure, expression pattern, ligand-binding profile, and intracellular effector system.
- G protein-coupled receptors Because of the vital role of G protein-coupled receptors in the communication between cells and their environment, such receptors are attractive targets for therapeutic intervention, for example by activating or antagonizing such receptors.
- receptors having a known ligand the identification of agonists or antagonists may be sought specifically to enhance or inhibit the action of the ligand.
- Some G protein-coupled receptors have roles in disease pathogenesis (e.g, certain chemokine receptors that act as HIV co-receptors may have a role in AIDS pathogenesis), and are attractive targets for therapeutic intervention even in the absence of knowledge of the natural ligand of the receptor.
- Other receptors are attractive targets for therapeutic intervention by virtue of their expression pattern in tissues or cell types that are themselves attractive targets for therapeutic intervention.
- Examples of this latter category of receptors include receptors expressed in immune cells, which can be targeted to either inhibit autoimmune responses or to enhance immune responses to fight pathogens or cancer; and receptors expressed in the brain or other neural organs and tissues, which are likely targets in the treatment of mental disorder, depression, bipolar disease, or other neurologbal disorders.
- This latter category of receptor is also useful as a marker for identifying and/or purifying (e.g., via fluorescence-activated cell sorting) cellular subtypes that express the receptor.
- Unfortunately only a limited number of G protein receptors from the central nervous system (CNS) are known. Thus, a need exists for G protein-coupled receptors that have been identified and show promise as targets for therapeutic intervention in a variety of animals, including humans.
- the present invention relates to an isolated nucleic acid molecule that comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of SEQ ID NO: 129 to SEQ IDNO:257, or a fragment thereof.
- the nucleic acid molecule encodes at least a portion of nGPCR-x.
- the nucleic acid molecule comprises a sequence that encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, or a fragment thereof.
- the nucleic acid molecule comprises a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, and fragments thereof.
- the present invention provides vectors which comprise the nucleic acid molecule of the invention.
- the vector is an expression vector.
- the present invention provides host cells which comprise the vectors of the invention.
- the host cells comprise expression vectors.
- the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128, said portion comprising at least 10 nudeotides.
- the present invention provides a method of producing a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, or a homolog or fragment thereof.
- the method comprising the steps of introducing a recombinant expression vector that includes a nucleotide sequence that encodes the polypeptide into a compatible host cell, growing the host cell under conditions for expression of the polypeptide and recovering the polypeptide.
- the present invention provides an isolated antibody which binds to an epitope on a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, or a homolog or fragment thereof.
- the present invention provides an method of inducing an immune response in a mammal against a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, or a homolog or fragment thereof.
- the method comprises administering to a mammal an amount of the polypeptide sufficient to induce said immune response.
- the present invention provides a method for identifying a compound which binds nGPCR-x.
- the method comprises the steps of contacting nGPCR-x with a compound and determining whether the compound binds nGPCR-x.
- the present invention provides a method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x.
- the method comprises the steps of contacting said nucleic acid molecule encoding nGPCR-x with a compound and determining whether said compound binds said nucleic acid molecule.
- the present invention provides a method for identifying a compound which modulates the activity of nGPCR-x.
- the method comprises the steps of contacting nGPCR-x with a compound and determining whether nGPCR-x activity has been modulated.
- the present invention provides a method of identifying an animal homolog of nGPCR-x.
- the method comprises the steps screening a nucleic acid database of the animal with a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128, or a portion thereof and determining whether a portion of said library or database is homologous to said sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128, or portion thereof.
- the present invention provides a method of identifying an animal homolog of nGPCR-x.
- the methods comprises the steps screening a nucleic acid library of the animal with a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or a portion thereof; and determining whether a portion of said library or database is homologous to said sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or a portion thereof.
- Another aspect of the present invention relates to methods of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor.
- the methods comprise the steps of assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR-x that is expressed in the brain.
- the nGPCR-x comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, and allelic variants thereof.
- a diagnosis of the disorder or predisposition is made from the presence or absence of the mutation.
- the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR-x in the nucleic acid correlates with an increased risk of developing the disorder.
- the present invention further relates to methods of screening for a nGPCR-x hereditary mental disorder genotype in a human patient.
- the methods comprise the steps of providing a biological sample comprising nucleic acid from the patient, in which the nucleic acid includes sequences corresponding to alleles of nGPCR-x.
- the presence of one or more mutations in the nGPCR-x allele is indicative of a hereditary mental disorder genotype.
- kits for screening a human subject to diagnose mental disorder or a genetic predisposition therefor include an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-x gene.
- the oligonucleotide comprises 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-x gene sequence or nGPCR-x coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution.
- the kit also includes a media packaged with the oligonucleotide. The media contains information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.
- the present invention further relates to methods of identifying nGPCR-x allelic variants that correlates with mental disorders.
- the methods comprise the steps of providing biological samples that comprise nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny, and detecting in the nucleic acid the presence of one or more mutations in an nGPCR-x that is expressed in the brain.
- the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, and allelic variants thereof.
- the nucleic acid includes sequences corresponding to the gene or genes encoding nGPCR-x.
- the one or more mutations detected indicate an allelic variant that correlates with a mental disorder.
- the present invention further relates to purified polynucleotides comprising nucleotide sequences encoding alleles of nGPCR-x from a human with mental disorder.
- the polynucleotide hybridizes to the complement of a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128 under the following hybridization conditions: (a) hybridization for 16 hours at 42° C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising O.lx SSC and 1% SDS.
- the polynucleotide that encodes nGPCR-x amino acid sequence of the human differs from a sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257 by at least one residue.
- the present invention also provides methods for identifying a modulator of biological activity of nGPCR-x comprising the steps of contacting a cell that expresses nGPCR- x in the presence and in the absence of a putative modulator compound and measuring nGPCR-x biological activity in the cell.
- the decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.
- the present invention further provides methods to identify compounds useful for the treatment of mental disorders.
- the methods comprise the steps of contacting a composition comprising nGPCR-x with a compound suspected of binding nGPCR-x.
- the binding between nGPCR-x and the compound suspected of binding nGPCR-x is detected.
- Compounds identified as binding nGPCR-x are candidate compounds useful for the treatment of mental disorder.
- Compounds identified as binding nGPCR-x may be further tested in other assays including, but not limited to, in vivo models, in order to confirm or quantitate their activity.
- the present invention further provides methods for identifying a compound useful as a modulator of binding between nGPCR-x and a binding partner of nGPCR-x.
- the methods comprise the steps of contacting the binding partner and a composition comprising nGPCR-x in the presence and in the absence of a putative modulator compound and detecting binding between the binding partner and nGPCR-x. Decreased or increased binding between the binding partner and nGPCR-x in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a related disease or disorder.
- Compounds identified as modulating binding between nGPCR-x and a nGPCR-x binding partner may be further tested in other assays including, but not limited to, in vivo models, in order to confirm or quantitate their activity as modulators.
- Another aspect of the present invention relates to methods of purifying a G protein from a sample containing a G protein.
- the methods comprise the steps of contacting the sample with an nGPCR-x for a time sufficient to allow the G protein to form a complex with the nGPCR-x; isolating the complex from remaining components of the sample; maintaining the complex under conditions which result in dissociation of the G protein from the nGPCR-x; and isolating said G protein from the nGPCR-x.
- Synthetic refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. “Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means.
- region is meant a physically contiguous portion of the primary structure of a biomolecule.
- a region is defined by a contiguous portion of the amino acid sequence of that protein.
- domain is herein defined as referring to a structural part of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains may be coextensive with regions or portions thereof; domains may also incorporate a portion of a biomolecule that is distinct from a particular region, in addition to all or part of that region . Examples of GPCR protein domains include, but are not limited to, the extracellular (i.
- transmembrane and cytoplasmic domains which are co-extensive with like-named regions of GPCRs; each of the seven transmembrane segments of a GPCR; and each of the loop segments (both extracellular and intracellular loops) connecting adjacent transmembrane segments.
- the term "activity" refers to a variety of measurable indicia suggesting or revealing binding, either direct or indirect; affecting a response, i.e. having a measurable affect in response to some exposure or stimulus, including, for example, the affinity of a compound for directly binding a polypeptide or polynucleotide of the invention, or, for example, measurement of amounts of upstream or downstream proteins or other similar functions after some stimulus or event.
- gpcr refers to a gene, cDNA, RNA or nucleic acid sequence
- GPCR refers to a protein, polypeptide, peptide, oligopeptide, or amino acid sequence.
- nGPCR-x refers to any of the nGPCRs taught herein, while specific reference to a nGPCR (for example nGPCR-2073) refers only to that specific nGPCR.
- antibody is meant to refer to complete, intact antibodies
- Fully intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies.
- binding means the physical or chemical interaction between two proteins or compounds or associated proteins or compounds or combinations thereof. Binding includes ionic, non-ionic, Hydrogen bonds, Van der Waals, hydrophobic interactions, etc.
- the physical interaction, the binding can be either direct or indirect, indirect being through or due to the effects of another protein or compound. Direct binding refers to interactions that do not take place through or due to the effect of another protein or compound but instead are without other substantial chemical intermediates. Binding may be detected in many different manners. As a non-limiting example, the physical binding interaction between a nGPCR-x of the invention and a compound can be detected using a labeled compound.
- functional evidence of binding can be detected using, for example, a cell transfected with and expressing a nGPCR-x of the invention. Binding of the transfected cell to a ligand of the nGPCR-x that was transfected into the cell provides functional evidence of binding. Other methods of detecting binding are well known to those of skill in the art.
- the term "compound” means any identifiable chemical or molecule, including, but not limited to, small molecule, peptide, protein, sugar, nucleotide, or nucleic acid, and such compound can be natural or synthetic.
- the term “complementary” refers to Watson-Cri ⁇ basepairing between nucleotide units of a nucleic acid molecule.
- the term "contacting" means bringing together, either directly or indirectly, a compound into physical proximity to a polypeptide or polynucleotide of the invention.
- the polypeptide or polynucleotide can be in any number of buffers, salts, solutions etc.
- Contacting includes, for example, placing the compound into a beaker, microtiter plate, cell culture flask, or a microarray, such as a gene chip, or the like, which contains the nucleic acid molecule, or polypeptide encoding the nGPCR or fragment thereof.
- homologous nucleotide sequence refers to sequences characterized by a homology, at the nucleotide level or amino acid level, of at least the specified percentage.
- Homologous nucleotide sequences include those sequences coding for isoforms of proteins. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes.
- Homologous nucleotide sequences include nucleotide sequences encoding for a protein of a species other than humans, including, but not limited to, mammals.
- Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein.
- a homologous nucleotide sequence does not, however, include the nucleotide sequence encoding other known GPCRs.
- Homologous amino acid sequences include those amino acid sequences which contain conservative amino acid substitutions and which polypeptides have the same binding and/or activity.
- a homologous amino acid sequence does not, however, include the amino acid sequence encoding other known GPCRs.
- Percent homology can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using the default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489, which is incorporated herein by reference in its entirety).
- isolated nucleic acid molecule refers to a nucleic acid molecule (DNA or RNA) that has been removed from its native environment.
- isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules.
- the terms “modulates” or “modifies” means an increase or decrease in the amount, quality, or effect of a particular activity or protein.
- oligonucleotide refers to a series of linked nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR). This short sequence is based on (or designed from) a genomic orcDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30 nucleotides. They are chemically synthesized and may be used as probes.
- probe refers to nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides, depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, or ELIS A- like technologies.
- preventing refers to decreasing the probability that an organism contracts or develops an abnormal condition.
- treating refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.
- a therapeutic effect refers to the inhibition or activation factors causing or contributing to the abnormal condition.
- a therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition.
- a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of cells; (b) inhibition (i.e., slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells.
- Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.
- abnormal condition refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism.
- An abnormal condition can relate to cell proliferation, cell differentiation, cell signaling, or cell survival.
- An abnormal condition may also include obesity, diabetic complications such as retinal degeneration, and irregularities in glucose uptake and metabolism, and fatty acid uptake and metabolism.
- Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.
- Abnormal differentiation conditions include, but are not limited to, neurodegenerative disorders, slow wound healing rates, and slow tissue graftinghealing rates.
- Abnormal cell signaling conditions include, but are not limited to, psychiatric disorders involving excess neurotransmitter activity.
- Abnormal cell survival conditions may also relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated.
- apoptosis programmed cell death
- a number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.
- administering relates to a method of incorporating a compound into cells or tissues of an organism.
- the abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism.
- Cells existing outside the organism can be maintained or grown in cell culture dishes.
- many techniques exist in the art to administer compounds including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications.
- multiple techniques exist in the art to administer the compounds including (but not limited to) cell microinjection techniques, transformation techniques and carrier techniques.
- the abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism.
- the effect of administering a compound on organism function can then be monitored.
- the organism is preferably a mouse, rat, rabbit, guinea pig or goat, more preferably a monkey or ape, and most preferably a human.
- amplification it is meant increased numbers of DNA or RNA in a cell compared with normal cells.
- “Amplification” as it refers to RNA can be the detectablepresence of RNA in cells, since in some normal cells there is no basal expression of RNA. In other normal cells, a basal level of expression exists, therefore in these cases amplification is the detection of at least 1 to 2-fold, and preferably more, compared to the basal level.
- stringent hybridization conditions refers to conditions under which a probe, primer, or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequencedependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. The T m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium.
- T m thermal melting point
- stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically ⁇ bout 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g. 10 to 50 nucleotides) and at least about 60°C for longer probes, primers or oligonucleotides.
- Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.
- amino acid sequences are presented in the amino to carboxy direction, from left to right.
- the amino and carboxy groups are not presented in the sequence.
- the nucleotide sequences are presented by single strand only, in the 5' to 3' direction, from left to right.
- Nucleotides and amino acids are represented in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission or (for amino acids) by three letters code.
- the present invention provides purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, both single and double-stranded, including splice variants thereof) that encode unknown G protein-coupled receptors heretofore termed novel GPCRs, or nGPCRs.
- novel GPCRs or nGPCRs.
- nGPCR-x where x is 2227-2229, 2280-2286, 2469-2479, 2480-2489, 2490-2499, 2500-2506, 2507-2516, 2517-2526, 2527-2536, 2537-2548, 2550-2554, 2555-2565, 2566-2576, and 2577-2587).
- Table 1 below identifies the novel gene sequence nGPCR-x designation, the SEQ ID NO: of the gene sequence, the SEQ ID NO: of the polypeptide encoded thereby, and the U.S. Provisional Application in which the gene sequence has been disclosed. Table 1
- nGPCR-2285 When a specific nGPCR is identified (for example nGPCR-2285), it is understood that only that specific nGPCR is being referred to. [00057] It is well known that GPCRs are expressed in many different tissues, including thebrain.
- nGPCR-x of the present invention may be useful, inter alia, for treating and/or diagnosing mental disorders. Following the techniques described in Example 5, below, those skilled in the art could readily ascertain if nGPCR-x is expressed in a particular tissue or region.
- the invention provides purified and isolated polynucleotides (e.g., cDNA, genomic
- DNA, synthetic DNA, RNA, or combinations thereof, whether single- or double-stranded) that comprise a nucleotide sequence encoding the amino acid sequence of the polypeptides of the invention are useful for recombinantly expressing the receptor and also for detecting expression of the receptor in cells (e.g., using Northern hybridization and in situ hybridization assays). Such polynucleotides also are useful in the design of antisense and other molecules for the suppression of the expression of nGPCR-x in a cultured cell, a tissue, or an animal; for therapeutic purposes; or to provide a model for diseases or conditions characterized by aberrant nGPCR-x expression.
- polynucleotides of the invention are entire isolated, non-recombinant native chromosomes of host cells.
- a preferred polynucleotide has a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, which correspond to naturally occurring nGPCR-x sequences. It will be appreciated that numerous other polynucleotide sequences exist that also encode nGPCR-x having the sequence selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, due to the well-known degeneracy of the universal genetic code.
- the invention also provides a purified and isolated polynucleotide comprising a nucleotide sequence that encodes a mammalian polypeptide, wherein the polynucleotide hybridizes to a polynucleotide having the sequence set forth in sequences selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or the non-coding strand complementary thereto, under the following hybridization conditions:
- the present invention relates to molecules which comprise the gene sequences that encode the nGPCRs; constructs and recombinant host cells incorporating the gene sequences; the novel GPCR polypeptides encoded by the gene sequences; antibodies to the polypeptides and homologs; kits employing the polynucleotides and polypeptides, and methods of making and using all of the foregoing.
- the present invention relates to homologs of the gene sequences and of the polypeptides and methods of making and using the same.
- Genomic DNA of the invention comprises the protein-coding region for a polypeptide of the invention and is also intended to include allelic variants thereof. It is widely understood that, for many genes, genomic DNA is transcribed into RNA transcripts that undergo one or more splicing events wherein intron (i.e., non-coding regions) of the transcripts are removed, or "spliced out.” RNA transcripts that can be spliced by alternative mechanisms, and therefore be subject to removal of different RNA sequences but still encode a nGPCR-x polypeptide, are referred to in the art as splice variants which are embraced by the invention.
- Splice variants comprehended by the invention therefore are encoded by the same original genomic DNA sequences but arise from distinct mRNA transcripts.
- Allelic variants are modified forms of a wild-type gene sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation.
- Allelic variants like wild type genes, are naturally occurring sequences (as opposed to non-naturally occurring variants that arise from in vitro manipulation).
- the invention also comprehends cDNA that is obtained through reverse transcription of an RNA polynucleotide encoding nGPCR-x (conventionally followed by second strand synthesis of a complementary strand to provide a double-stranded DNA).
- Preferred DNA sequences encoding human nGPCR-x polypeptides are selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128.
- a preferred DNA of the invention comprises a double stranded molecule along with the complementary molecule (the "non-coding strand” or “complement") having a sequence unambiguously deducible from the coding strand according to Watson-Crick base-pairing rules for DNA.
- polynucleotides encoding the nGPCR-x polypeptide selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, which differ in sequence from the polynucleotides selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, by virtue of the well-known degeneracy of the universal nuclear genetic code.
- the invention further embraces other species, preferably mammalian, homologs of the human nGPCR-x DNA.
- Species homologs sometimes referred to as "orthologs," in general, share at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homology with human DNA of the invention.
- percent sequence "homology" with respect to polynucleotides of the invention may be calculated as the percentage of nucleotide bases in the candidate sequence that are identical to nucleotides in the nGPCR-x sequence set forth in sequences selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
- Polynucleotides of the invention permit identification and isolation of polynucleotides encoding related nGPCR-x polypeptides, such as human allelic variants and species homologs, by well-known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR).
- related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to nGPCR-x and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of nGPCR-x.
- Non-human species genes encoding proteins homologous to nGPCR-x can also be identified by Southern and/or PCR analysis and are useful in animal models for nGPCR-x disorders.
- Knowledge of the sequence of a human nGPCR-x DNA also makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding nGPCR-x expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like.
- Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express nGPCR-x.
- Polynucleotides of the invention may also provide a basis for diagnostic methods useful for identifying a genetic alteration(s) in a nGPCR-x locus that underlies a disease state or states, which information is useful both for diagnosis and for selection of therapeutic strategies.
- the nGPCR-x nucleotide sequences disclosed herein may be used to identify homologs of the nGPCR-x, in other animals, including but not limited to humans and other mammals, and invertebrates. Any of the nucleotide sequences disclosed herein, or any portion thereof, can be used, for example, as probes to screen databases or nucleic acid libraries, such as, for example, genomic or cDNA libraries, to identify homologs, using screening procedures well known to those skilled in the art.
- homologs having at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 100% homology with nGPCR-x sequences can be identified.
- One preferred embodiment of the present invention provides an isolated nucleic acid molecule comprising a sequence homologous sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128, and fragments thereof.
- Another preferred embodiment provides an isolated nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, and fragments thereof.
- fragments of nGPCR-x-encoding polynucleotides comprise at least 10, and preferably at least 12, 14, 16, 18, 20, 25, 50, or 75 consecutive nucleotides of a polynucleotide encoding nGPCR-x.
- fragment polynucleotides of the invention comprise sequences unique to the nGPCR-x-encoding polynucleotide sequence, and therefore hybridize under highly stringent or moderately stringent conditions only (i.e., "specifically") to polynucleotides encoding nGPCR-x (or fragments thereof).
- Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full-length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs routinely utilized in the art, e.g., those made available in public sequence databases. Such sequences also are recognizable from Southern hybridization analyses to determine the number of fragments of genomic DNA to which a polynucleotide will hybridize. Polynucleotides of the invention can be labeled in a manner that permits their detection, including radioactive, fluorescent, and enzymatic labeling.
- Fragment polynucleotides are particularly useful as probes for detection of full-length or fragments of nGPCR-x polynucleotides.
- One or more polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding nGPCR-x, or used to detect variations in a polynucleotide sequence encoding nGPCR-x.
- the invention also embraces DNAs encoding nGPCR-x polypeptides that hybridize under moderately stringent or high stringency conditions to the non-coding strand, or complement, of the polynucleotides set forth in sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128.
- Exemplary highly stringent hybridization conditions are as follows: hybridization at
- nucleotide sequence information disclosed in the present invention, one skilled in the art can identify and obtain nucleotide sequences which encode nGPCR-x from different sources (i.e., different tissues or different organisms) through a variety of means well known to the skilled artisan and as disclosed by, for example, Sambrook et al., "Molecular cloning: a laboratory manual", Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), which is incorporated herein by reference in its entirety.
- DNA that encodes nGPCR-x may be obtained by screening of mRNA, cDNA, or genomic DNA with oligonucleotide probes generated from the nGPCR-x gene sequence information provided herein. Probes may be labeled with a detectable group, such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with procedures known to the skilled artisan and used in conventional hybridization assays, as described by, for example, Sambrook et al.
- a detectable group such as a fluorescent group, a radioactive atom or a chemiluminescent group
- a nucleic acid molecule comprising any of the nGPCR-x nucleotide sequences described above can alternatively be synthesized by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers produced from the nucleotide sequences provided herein.
- PCR polymerase chain reaction
- the PCR reaction provides a method for selectively increasing the concentration of a particular nucleic acid sequence even when that sequence has not been previously purified and is present only in a single copy in a particular sample.
- the method can be used to amplify either single or double-stranded DNA.
- the essence of the method involves the use of two oligonucleotide probes to serve as primers for the template-dependent, polymerase mediated replication of a desired nucleic acid molecule.
- Automated sequencing methods can be used to obtain or verify the nucleotide sequence of nGPCR-x.
- the nGPCR-x nucleotide sequences of the present invention are believed to be 100% accurate.
- nucleotide sequence obtained by automated methods may contain some errors.
- Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule.
- the actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art.
- An error in a sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation.
- nucleic acid molecules of the present invention are useful for screening for restriction fragment length polymorphism (RFLP) associated with certain disorders, as well as for genetic mapping.
- RFLP restriction fragment length polymorphism
- vectors or recombinant expression vectors, comprising any of the nucleic acid molecules described above.
- Vectors are used herein either to amplify DNA or RNA encoding nGPCR-x and/or to express DNA which encodes nGPCR-x.
- Preferred vectors include, but are not limited to, plasmids, phages, cosmids, episomes, viral particles or viruses, and integratable DNA fragments (i.e, fragments integratable into the host genome by homologous recombination).
- Preferred viral particles include, but are not limited to, adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno- associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses.
- Preferred expression vectors include, but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech).
- expression vectors include, but are not limited to, pSPORTTM vectors, pGEMTM vectors (Promega), pPROEXvectorsTM (LTI, Bethesda, MD), BluescriptTM vectors (Stratagene), pQETM vectors (Qiagen), pSE420TM (Invitrogen), and ⁇ YES2TM(Invitrogen).
- Expression constructs preferably comprise GPCR-x-encoding polynucleotides operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator.
- Expression control DNA sequences include promoters, enhancers, operators, and regulatory element binding sites generally, and aie typically selected based on the expression systems in which the expression construct is to be utilized. Preferred promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression.
- Expression constructs of the invention may also include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also include sequences that facilitate, and preferably promote, homologous recombination in a host cell. Preferred constructs of the invention also include sequences necessary for replication in a host cell.
- Expression constructs are preferably utilized for production of an encoded protein, but may also be utilized simply to amplify a nGPCR-x-encoding polynucleotide sequence.
- the vector is an expression vector wherein the polynucleotide of the invention is operatively linked to a polynucleotide comprising an expression control sequence.
- Autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors incorporating polynucleotides of the invention are also provided.
- Preferred expression vectors are replicable DNA constructs in which a DNA sequence encoding nGPCR-x is operably linked or connected to suitable control sequences capable of effecting the expression of the nGPCR-x in a suitable host.
- DNA regions are operably linked or connected when they are functionally related to each other.
- a promoter is operably linked or connected to a coding sequence if it controls the transcription of the sequence.
- Amplification vectors do not require expression control domains, but rather need only the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants.
- the need for control sequences in the expression vector will vary depending upon the host selected and the transformation method chosen.
- control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding and sequences which control the termination of transcription and translation.
- Preferred vectors preferably contain a promoter that is recognized by the host organism.
- the promoter sequences of the present invention may be prokaryotic, eukaryotic or viral.
- suitable prokaryotic sequences include the P R and P L promoters of bacteriophage lambda (The bacteriophage Lambda, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1973), which is incorporated herein by reference in its entirety; Lambda II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1980), which is incorporated herein by reference in its entirety); the trp, recA, heat shock, and lacZ promoters of E.
- Additional promoters include, but are not limited to, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metalothionein.
- Additional regulatory sequences can also be included in preferred vectors.
- Preferred examples of suitable regulatory sequences are represented by the Shine-Dalgarno of the replicase gene of the phage MS-2 and of the gene ell of bacteriophage lambda.
- the Shine- Dalgarno sequence may be directly followed by DNA encoding nGPCR-x and result in the expression of the mature nGPCR-x protein.
- suitable expression vectors can include an appropriate marker that allows the screening of the transformed host cells.
- the transformation of the selected host is carried out using any one of the various techniques well known to the expert in the art and described in Sambrook et al., supra.
- An origin of replication can also be provided either by construction of the vector to include an exogenous origin or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter may be sufficient.
- a selectable marker is dihydrofolate reductase (DHFR) or thymidine kinase (see, U.S. Patent No. 4,399,216).
- Nucleotide sequences encoding GPCR-x may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesiderable joining, and ligation with appropriate ligases. Techniques for such manipulation are disclosed by Sambrook et & ⁇ .,supra and are well known in the art. Methods for construction of mammalian expression vectors are disclosed in, for example, Okayama et al, Mol. Cell. Biol, 1983,3, 280, Cosman et al, Mol. Immunol, 1986, 23, 935, Cosman et al, Nature, 1984, 312, 768, EP-A-0367566, and WO 91/18982, each of which is incorporated herein by reference in its entirety. Host cells
- host cells are provided, induding prokaryotic and eukaryotic cells, comprising a polynucleotide of the invention (or vector of the invention) in a manner that permits expression of the encoded nGPCR-x polypeptide.
- Polynucleotides of the invention may be introduced into the host cell as part of a circular plasmid, or as linear DNA comprising an isolated protein coding region or a viral vector.
- Methods for introducing DNA into the host cell that are well known and routinely practiced in the art include transformation, transfection, electroporation, nuclear injection, or fusion with carriers such as liposomes, micelles, ghost cells, and protoplasts.
- Expression systems of the invention include bacterial, yeast, fungal, plant, insect, invertebrate, vertebrate, and mammalian cells systems.
- the invention provides host cells that are transformed or transfected (stably or transiently) with polynucleotides of the invention or vectors of the invention. As stated above, such host cells are useful for amplifying the polynucleotides and also for expressing the nGPCR-x polypeptide or fragment thereof encoded by the polynucleotide.
- the invention provides a method for producing a nGPCR-x polypeptide (or fragment thereof) comprising the steps of growing a host eel of the invention in a nutrient medium and isolating the polypeptide or variant thereof from the cell or the medium.
- nGPCR-x is a seven transmembrane receptor, it will be appreciated that, for some applications, such as certain activity assays, the preferable isolation may involve isolation of cell membranes containing the polypeptide embedded therein, whereas for other applications a more complete isolation may be preferable.
- transformed host cells having an expression vector comprising any of the nucleic acid molecules described above are provided.
- Expression of the nucleotide sequence occurs when the expression vector is introduced into an appropriate host cell.
- Suitable host cells for expression of the polypeptides of the invention include, but are not limited to, prokaryotes, yeast, and eukaryotes. If a prokaryotic expression vector is employed, then the appropriate host cell would be any prokaryotic cell capable of expressing the cloned sequences.
- Suitable prokaryotic cells include, but are not limited to, bacteria of the genera Escherichia, Bacillus, Salmonella, Pseudomonas, Streptomyces, and Staphylococcus.
- eukaryotic cells are cells of higher eukaryotes.
- Suitable eukaryotic cells include, but are not limited to, nonhuman mammalian tissue culture cells and human tissue culture cells.
- Preferred host cells include, but are not limited to, insect cells, HeLa cells, Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (COS cells), human HEK-293 cells, and murine 3T3 fibroblasts. Propagation of such cells in cell culture has become a routine procedure (see, Tissue Culture, Academic Press, Kruse and Patterson, eds. (1973), which is incorporated herein by reference in its entirety).
- yeast host may be employed as a host cell.
- Preferred yeast celt include, but are not limited to, the genera Saccharomyces, Pichia, and Kluveromyces.
- Preferred yeast hosts are S. cerevisiae and P. pastoris.
- Preferred yeast vectors can contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replication sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene.
- ARS autonomously replication sequence
- Shuttle vectors for replication in both yeast andE. coli are also included herein.
- insect cells may be used as host cells.
- the polypeptides of the invention are expressed using a baculovirus expression system (see, Luckow et al, Bio/Technology, 1988, 6, 47, Baculovirus Expression Vectors: A Laboratory Manual, O'Rielly et al. (Eds.), W.H. Freeman and Company, New York, 1992, and U.S. Patent No. 4,879,236, each of which is incorporated herein by reference in its entirety).
- the MAXBACTM complete baculovirus expression system can, for example, be used for production in insect cells.
- Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with nGPCR-x.
- Host cells of the invention are also useful in methods for the large-scale production of nGPCR-x polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells, or from the medium in which the cells are grown, by purification methods known in the art, e.g., conventional chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusion filtration, cation or anion exchange chromatography, high pressure liquid chromatography (HPLC), reverse phase HPLC, and the like.
- HPLC high pressure liquid chromatography
- Still other methods of purification include those methods wherein the desired protein is expressed and purified as a fusion protein having a specific tag, label, or chelating moiety that is recognized by a specific binding partner or agent.
- the purified protein can be cleaved to yield the desired protein, or can be left as an intact fusion protein. Cleavage of the fusion component may produce a form of the desired protein having additional amino acid residues as a result of the cleavage process.
- nGPCR-x DNA sequences allows for modification of cells to permit, or increase, expression of endogenous nGPCR-x.
- Cells can be modified (e.g., by homologous recombination) to provide increased expression by replacing, in whole or in part, the naturally occurring nGPCR-x promoter with all or part of a heterologous promoter so that the cells express nGPCR-x at higher levels.
- the heterologous promoter is inserted in such a manner that it is operatively linked to endogenous nGPCR-x encoding sequences.
- amplifiable marker DNA e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamoyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase
- intron DNA may be inserted along with the heterologous promoter DNA. If linked to the nGPCR-x coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the nGPCR-x coding sequences in the cells.
- Knock-outs [00097]
- the DNA sequence information provided by the present invention also makes possible the development (e.g., by homologous recombination or "knock-out” strategies; see Capecchi, Science 244 ⁇ 2S8-1292 (1989), which is incorporated herein by reference) of animals that fail to express functional nGPCR-x or that express a variant of nGPCR-x.
- Such animals especially small laboratory animals such as rats, rabbits, and mice) are useful as models for studying them vivo activities of nGPCR-x and modulators of nGPCR-x.
- Antisense Also made available by the invention are anti-sense polynucleotides that recognize and hybridize to polynucleotides encoding nGPCR-x. Full-length and fragment anti-sense polynucleotides are provided. Fragment antisense molecules of the invention include (i) those that specifically recognize and hybridize to nGPCR-x RNA (as determined by sequence comparison of DNA encoding nGPCR-x to DNA encoding other known molecules). Identification of sequences unique to nGPCR-x encoding polynucleotides can be deduced through use of any publicly available sequence database, and/or through use of commercially available sequence comparison programs.
- Anti-sense polynucleotides are particularly relevant to regulating expression of nGPCR-x by those cells expressing nGPCR- x mRNA.
- Antisense nucleic acids preferably 10 to 30 base-pair oligonucleotides capable of specifically binding to nGPCR-x expression control sequences or nGPCR-x RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome).
- the antisense nucleic acid binds to the nGPCR-x target nucleotide sequence in the cell and prevents transcription and/or translation of the target sequence.
- Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention.
- the antisense oligonucleotides may be further modified by adding poly-L- lysine, transferrin polylysine, or cholesterol moieties at their 5' end. Suppression of nGPCR-x expression at either the transcriptional or translational level is useful to generate cellular or animal models for diseases/conditions characterized by aberrant nGPCR-x expression.
- Antisense oligonucleotides, or fragments of sequences selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or sequences complementary or homologous thereto, derived from the nucleotide sequences of the present invention encoding nGPCR-x are useful as diagnostic tools for probing gene expression in various tissues.
- tissue can be probed in situ with oligonucleotide probes carrying detectable groups by conventional autoradiography techniques to investigate native expression of this enzyme or pathological conditions relating thereto.
- Antisense oligonucleotides are preferably directed to regulatory regions of sequences selected from the group consisting of SEQ ID NO:l to SEQ ID NO:128, or mRNA corresponding thereto, including, but not limited to, the initiation codon, TATA box, enhancer sequences, and the like.
- nGPCR-x sequences taught in the present invention facilitate the design of novel transcription factors for modulating nGPCR-x expression in native cells and animals, and cells transformed or transfected with nGPCR-x polynucleotides.
- the Cys_-His 2 zinc finger proteins which bind DNA via their zinc finger domains, have been shown to be amenable to structural changes that lead to the recognition of different target sequences. These artificial zinc finger proteins recognize specific target sites with high affinity and low dissociation constants, and are able to act as gene switches to modulate gene expression.
- nGPCR-x target sequence of the present invention facilitates the engineering of zinc finger proteins specific for the target sequence using known methods such as a combination of structure-based modeling and screening of phage display libraries (Segal et al, Proc. Natl. Acad. Sci. (USA) 96:2758-2763 (1999); Liu et al, Proc. Natl. Acad. Sci. (USA) 94:5525-5530 (1997); Greisman et /., Science 275:657-661 (1997); Choo et al, J. Mol. Biol. 273:525-532 (1997)).
- Each zinc finger domain usually recognizes three or more base pairs.
- a zinc finger protein consisting of 6 tandem repeats of zinc fingers would be expected to ensure specificity for a particular sequence (Segal et al.)
- the artificial zinc finger repeats designed based on nGPCR-x sequences, are fused to activation or repression domains to promote or suppress nGPCR-x expression (Liu et al.)
- the zinc finger domains can be fused to the TATA box-binding factor (TBP) with varying lengths of linker region between the zinc finger peptide and the TBP to create either transcriptional activators or repressors (Kim et al, Proc. Natl. Acad. Sci.
- Such proteins and polynucleotides that encode them have utility for modulating nGPCR-x expression z'.z vivo in both native cells, animals and humans; and/or cells transfected with nGPCR-x-encoding sequences.
- the novel transcription factor can be delivered to the target cells by transfecting constructs that express the transcription factor (gene therapy), or by introducing the protein.
- Engineered zinc finger proteins can also be designed to bind RNA sequences for use in therapeutics as alternatives to antisense or catalytic RNA methods (McCollet al, Proc. Natl. Acad. Sci. (USA) 96:9521-9526 (1997); Wu et al, Proc. Natl.
- the present invention contemplates methods of designing such transcription factors based on the gene sequence of the invention, as well as customized zinc finger proteins, that are useful to modulate nGPCR-x expression in cells (native or transformed) whose genetic complement includes these sequences.
- the invention also provides purified and isolated mammalian nGPCR-x polypeptides encoded by a polynucleotide of the invention.
- a human nGPCR-x polypeptide comprising the amino acid sequence set out in sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, or fragments thereof comprising an epitope specific to the polypeptide.
- epitope specific to is meant a portion of the nGPCR receptor that is recognizable by an antibody that is specific for the nGPCR, as defined in detail below.
- sequences provided are particular human sequences, the invention is intended to include within its scope other human allelic variants; non-human mammalian forms of nGPCR-x, and other vertebrate forms of nGPCR-x.
- the invention provides a purified and isolated polypeptide comprising at least one extracellular domain (e.g., the N-terminal extracellular domain or one of the three extracellular loops) of nGPCR-x. Purified and isolated polypeptides comprising the N-terminal extracellular domain of nGPCR-x are highly preferred.
- a purified and isolated polypeptide comprising a nGPCR-x fragment selected from the group consisting of the N-terminal extracellular domain of nGPCR-x, transmembrane domains of nGPCR-x, an extracellular loop connecting transmembrane domains of nGPCR-x, an intracellular loop connecting transmembrane domains of nGPCR-x, the C-terminal cytoplasmic region of nGPCR-x, and fusions thereof.
- Such fragments may be continuous portions of the native receptor.
- knowledge of the nGPCR-x gene and protein sequences as provided herein permits recombining of various domains that are not contiguous in the native protein.
- nGPCR-x was shown to contain transmembrane-spanning domains.
- the invention also embraces polypeptides that have at least 99%, at least 95%, at least
- Percent amino acid sequence "identity" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
- Percent sequence "homology" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.
- percent homology is calculated as the percentage of amino acid residues in the smaller of two sequences which align with identical amino acid residue in the sequence being compared, when four gaps in a length of 100 amino acids may be introduced to maximize alignment (Dayhoff, in Atlas of Protein Sequence and Structure Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972), incorporated herein by reference).
- Polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention.
- Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention.
- Glycosylated and non-glycosylated forms of nGPCR-x polypeptides are embraced by the invention.
- the invention also embraces variant (or analog) nGPCR-x polypeptides.
- insertion variants are provided wherein one or more amino acid residues supplement a nGPCR-x amino acid sequence. Insertions may be located at either or both termini of the protein, or may be positioned within internal regions of the nGPCR-x amino acid sequence. Insertional variants with additional residues at either or both termini can include, for example, fusion proteins and proteins including amino acid tags or labels.
- Insertion variants include nGPCR-x polypeptides wherein one or more amino acid residues are added to a nGPCR-x acid sequence or to a biologically active fragment thereof.
- Variant products of the invention also include mature nGPCR-x products, i. e. , nGPCR-x products wherein leader or signal sequences are removed, with additional amino terminal residues.
- the additional amino terminal residues may be derived from another protein, or may include one or more residues that are not identifiable as being derived from specific proteins.
- nGPCR-x products with an additional methionine residue at position -1 are contemplated, as are variants with additional methionine and lysine residues atpositions-2 and -1 (Mef 2 -Lys "! -nGPCR-x).
- Variants of nGPCR-x with additional Met, Met-Lys, Lys residues are particularly useful for enhanced recombinant protein production in bacterial host cells.
- the invention also embraces nGPCR-x variants having additional amino acid residues that result from use of specific expression systems.
- use of commercially available vectors that express a desired polypeptide as part of a glutathione-S-transferase (GST) fusion product provides the desired polypeptide having an additional glycine residue at position -1 after cleavage of the GST component from the desired polypeptide.
- GST glutathione-S-transferase
- Insertional variants also include fusion proteins wherein the amino terminus and/or the carboxy terminus of nGPCR-x is/are fused to another polypeptide.
- the invention provides deletion variants wherein one or more amino acid residues in a nGPCR-x polypeptide are removed.
- Deletions can be effected at one or both termini of the nGPCR-x polypeptide, or with removal of one or more non-terminal amino acid residues of nGPCR-x.
- Deletion variants therefore, include all fragments of a nGPCR-x polypeptide.
- the invention also embraces polypeptide fragments of sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, wherein the fragments maintain biological (e.g., ligand binding and/or intracellular signaling) immunological properties of a nGPCR-x polypeptide.
- an isolated nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, and fragments thereof, wherein the nucleic acid molecule encoding at least a portion of nGPCR-x.
- the isolated nucleic acid molecule comprises a sequence that encodes a polypeptide comprising sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, and fragments thereof.
- polypeptide fragments comprise at least 5, 10, 15, 20,
- polypeptide fragments display antigenic properties unique to, or specific for, human nGPCR-x and its allelic and species homologs. Fragments of the invention having the desired biological and immunological properties can be prepared by any of the methods well known and routinely practiced in the art.
- the invention provides substitution variants of nGPCR-x polypeptides.
- Substitution variants include those polypeptides wherein one or more amino acid residues of a nGPCR-x polypeptide are removed and replaced with alternative residues.
- the substitutions are conservative in nature; however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may be defined as set out in Tables 2, 3, or 4 below.
- Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure.
- a conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties.
- Exemplary conservative substitutions are set out in Table 2 (from WO 97/09433, page 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96), immediately below.
- polypeptides of the invention is intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues.
- the modifications may be covalent in nature, and include for example, chemical bonding with polymers, lipids, other organic, and inorganic moieties.
- Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the targeting capacity of the polypeptide for desired cells, tissues, or organs.
- the invention further embraces nGPCR-x polypeptides that have been covalently modified to include one or more water-soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol.
- Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.
- compositions comprising purified polypeptides of the invention.
- Preferred compositions comprise, in addition to the polypeptide of the invention, a pharmaceutically acceptable (i.e., sterile and non-toxic) liquid, semisolid, or solid diluent that serves as a pharmaceutical vehicle, excipient, or medium. Any diluent known in the art may be used.
- Exemplary diluents include, but are not limited to, water, saline solutions, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, glycerol, calcium phosphate, mineral oil, and cocoa butter.
- Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in assays of the invention and in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.
- the G protein-coupled receptor functions through a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) coupled to the intracellular portion of the G protein-coupled receptor molecule. Accordingly, the G protein-coupled receptor has a specific affinity to G protein. G proteins specifically bind to guanine nucleotides.
- G proteins may be isolated using commercially available anti-G protein antibodies or isolated G protein-coupled receptors. Similarly, G proteins may be detected in a sample isolated using commercially available detectable anti-G protein antibodies or isolated G protein-coupled receptors.
- the isolated nGPCR-x proteins of the present invention are useful to isolate and purify G proteins from samples such as cell ly sates.
- Example 15 below sets forth an example of isolation of G proteins using isolated nGPCR-x proteins. Such methodolgy may be used in place of the use of commercially available anti-G protein antibodies which are used to isolate G proteins.
- G proteins may be detected using n- GPCR-x proteins in place of commercially available detectable anti-G protein antibodies. Since nGPCR-x proteins specifically bind to G proteins, they can be employed in any specific use where G protein specific affinity is required such as those uses where commercially available anti-G protein antibodies are employed. Antibodies
- antibodies e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention
- Preferred antibodies of the invention are human antibodies that are produced and identified according to methods described in WO93/11236, published June 20, 1993, which is incorporated herein by reference in its entirety.
- Antibody fragments, including Fab, Fab', F(ab') 2 , and F v are also provided by the invention.
- variable regions of the antibodies of the invention recognize and bind nGPCR-x polypeptides exclusively (i.e., are able to distinguish nGPCR-x polypeptides from other known GPCR polypeptides by virtue of measurable differences in binding affinity, despite the possible existence of localized sequence identity, homology, or similarity between nGPCR-x and such polypeptides).
- specific antibodies may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELIS A techniques) through interactions with sequences outside the variable region of the antibodies, and, in particular, in the constant region of the molecule.
- the invention provides an antibody that is specific for the nGPCR-x of the invention.
- Antibody specificity is described in greater detail below. However, it should be emphasized that antibodies that can be generated from polypeptides that have previously been described in the literature and that are capable of fortuitously cross-reacting with nGPCR-x (e.g., due to the fortuitous existence of a similar epitope in both polypeptides) are considered “cross-reactive" antibodies. Such cross-reactive antibodies are not antibodies that are "specific" for nGPCR-x. The determination of whether an antibody is specific for nGPCR-x or is cross-reactive with another known receptor is made using any of several assays, such as Western blotting assays, that are well known in the art. For identifying cells that express nGPCRx and also for modulating nGPCR-x-ligand binding activity, antibodies that specifically bind to an extracellular epitope of the nGPCR-x are preferred.
- the invention provides monoclonal antibodies. Hybridomas that produce such antibodies also are intended as aspects of the invention. In yet another variation, the invention provides a humanized antibody. Humanized antibodies are useful for in vivo therapeutic indications.
- the invention provides a cell-free composition comprising polyclonal antibodies, wherein at least one of the antibodies is an antibody of the invention specific for nGPCR-x.
- Antisera isolated from an animal is an exemplary composition, as is a composition comprising an antibody fraction of an antisera that has been resuspended in water or in another diluent, excipient, or carrier.
- the invention provides an anti-idiotypic antibody specific for an antibody that is specific for nGPCR-x.
- the invention provides a polypeptide comprising a fragment of a nGPCR-x-specific antibody, wherein the fragment and the polypeptide bind to the nGPCR-x.
- the invention provides polypeptides that are single chain antibodies and CDR-grafted antibodies.
- Non-human antibodies may be humanized by any of the methods known in the art.
- the non-human CDRs are inserted into a human antibody or consensus antibody framework sequence. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.
- Antibodies of the invention are useful for, e.g., therapeutic purposes (by modulating activity of nGPCR-x), diagnostic purposes to detect or quantitate nGPCR-x, and purification of nGPCR-x.
- Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended.
- a kit of the invention also includes a control antigen for which the antibody is immunospecific.
- nGPCR-x Mutations in the nGPCR-x gene that result in loss of normal function of the nGPCR-x gene product underlie nGPCR-x-related human disease states.
- the invention comprehends gene therapy to restore nGPCR-x activity to treat those disease states.
- Delivery of a functional nGPCR-x gene to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), oxex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no.
- compositions including pharmaceutical compositions, comprising any of the nucleic acid molecules or recombinant expression vectors described above and an acceptable carrier or diluent.
- the carrier or diluent is pharmaceutically acceptable.
- Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field, which is incorporated herein by reference in its entirety.
- Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used.
- the formulations are sterilized by commonly used techniques.
- compositions comprising polypeptides, polynucleotides, or antibodies of the invention that have been formulated with,e.g., a pharmaceutically acceptable carrier.
- the invention also provides methods of using antibodies of the invention.
- the invention provides a method for modulating ligand binding of a nGPCR-x comprising the step of contacting the nGPCR-x with an antibody specific for the nGPCR-x, under conditions wherein the antibody binds the receptor.
- GPCRs are expressed in many different tissues and regions, including in the brain. GPCRs that may be expressed in the brain, such as nGPCR- x, provide an indication that aberrant nGPCR-x signaling activity may correlate with one or more neurological or psychological disorders.
- the invention also provides a method for treating a neurological or psychiatric disorder comprising the step of administering to a mammal in need of such treatment an amount of an antibody-like polypeptide of the invention that is sufficient to modulate ligand binding to a nGPCR-x in neurons of the mammal.
- nGPCR-x may also be expressed in other tissues, including but not limited to, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, thyroid gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues.
- nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Kits
- kits including pharmaceutical kits.
- the kits can comprise any of the nucleic acid molecules described above, any of the polypeptides described above, or any antibody which binds to a polypeptide of the invention as described above, as well as a negative control.
- the kit preferably comprises additional components, such as, for example, instructions, solid support, reagents helpful for quantification, and the like.
- the invention features methods for detection of a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a polypeptide having sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probetarget region hybrid as an indication of the disease.
- the disease is selected from the group consisting of thyroid disorders (e.g. thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (e.g., Crohn's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc.); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dys
- Kits may be designed to detect either expression of polynucleotides encoding nGPCR-x expressed in the brain or the nGPCR-x proteins themselves in order to identify tissue as being neurological.
- oligonucleotide hybridization kits can be provided which include a container having an oligonucleotide probe specific for the nGPCR-x-specific DNA and optionally, containers with positive and negative controls and/or instructions.
- PCR kits can be provided which include a container having primers specific for the nGPCR-x- specific sequences, DNA and optionally, containers with size markers, positive and negative controls and/or instructions.
- Hybridization conditions should be such that hybridization occurs only with the genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined supra.
- the diseases for which detection of genes in a sample could be diagnostic include diseases in which nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells.
- amplification is meant increased numbers of DNA or RNA in a cell compared with normal cells.
- the diseases that could be diagnosed by detection of nucleic acid in a sample preferably include central nervous system and metabolic diseases.
- the test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids.
- the samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.
- immunoassay kits can be provided which have containers container having antibodies specific for the nGPCR-x-protein and optionally, containers with positive and negative controls and/or instructions.
- Kits may also be provided useful in the identification of GPCR binding partners such as natural ligands or modulators (agonists or antagonists).
- Substances useful for treatment of disorders or diseases preferably show positive results in one or more in vitro assays for an activity corresponding to treatment of the disease or disorder in question.
- Substances that modulate the activity of the polypeptides preferably include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and inhibitors of protein kinases.
- Another aspect of the present invention is directed to methods of inducing an immune response in a mammal against a polypeptide of the invention by administering to the mammal an amount of the polypeptide sufficient to induce an immune response.
- the amount willbe dependent on the animal species, size of the animal, and the like but can be determined by those skilled in the art.
- the invention also provides assays to identify compounds that bind nGPCR-x.
- One such assay comprises the steps of: (a) contacting a composition comprising a nGPCR-x with a compound suspected of binding nGPCR-x; and (b) measuring binding between the compound and nGPCR-x.
- the composition comprises a cell expressing nGPCR-x on its surface.
- isolated nGPCR-x or cell membranes comprising nGPCR-x are employed.
- the binding may be measured directly, e.g., by using a labeled compound, or may be measured indirectly by several techniques, including measuring intracellular signaling of nGPCR-x induced by the compound (or measuring changes in the level of nGPCR-x signaling).
- steps (a) and (b) compounds identified as binding nGPCR-x may be tested in other assays including, but not limited to, in vivo models, to confirm or quantitate binding to nGPCR- x.
- binding molecules including natural ligands and synthetic compounds, can be identified or developed using isolated or recombinant nGPCR-x products, nGPCR-x variants, or preferably, cells expressing such products. Binding partners are useful for purifying nGPCR-x products and detection or quantification of nGPCR-x products in fluid and tissue samples using known immunological procedures. Binding molecules are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biological activities of nGPCR-x, especially those activities involved in signal transduction.
- the DNA and amino acid sequence information provided by the present invention also makes possible identification of binding partner compounds with which a nGPCR-x polypeptide or polynucleotide will interact.
- Methods to identify binding partner compounds include solution assays, in vitro assays wherein nGPCR-x polypeptides are immobilized, and cell-based assays. Identification of binding partner compounds of nGPCR-x polypeptides provides candidates for therapeutic or prophylactic intervention in pathologies associated with nGPCR-x normal and aberrant biological activity.
- the invention includes several assay systems for identifying nGPCR-x binding partners.
- methods of the invention comprise the steps of (a) contacting a nGPCR-x polypeptide with one or more candidate binding partner compounds and (b) identifying the compounds that bind to the nGPCR-x polypeptide. Identification of the compounds that bind the nGPCR-x polypeptide can be achieved by isolating the nGPCR-x polypeptide/binding partner complex, and separating the binding partner compound from the nGPCR-x polypeptide.
- nGPCR-x polypeptide/binding partner complex is isolated using an antibody immunospecific for either the nGPCR-x polypeptide or the candidate binding partner compound.
- either the nGPCR-x polypeptide or the candidate binding partner compound comprises a label or tag that facilitates its isolation
- methods of the invention to identify binding partner compounds include a step of isolating the nGPCR-x polypeptide/binding partner complex through interaction with the label or tag.
- An exemplary tag of this type is a poly-histidine sequence, generally around six histidine residues, that permits isolation of a compound so labeled using nickel chelation.
- Other labels and tags such as the FLAG ® tag (Eastman Kodak, Rochester, NY), well known and routinely used in the art, are embraced by the invention.
- the invention provides a method comprising the steps of (a) contacting an immobilized nGPCR-x polypeptide with a candidate binding partner compound and (b) detecting binding of the candidate compound to the nGPCR-x polypeptide.
- the candidate binding partner compound is immobilized and binding of nGPCR-x is detected. Immobilization is accomplished using any of the methods well known in the art, including covalent bonding to a support, a bead, or a chromatographic resin, as well as non-covalent, high affinity interactions such as antibody binding, or use of streptavidin/biotin binding wherein the immobilized compound includes a biotin moiety.
- Detection of binding can be accomplished (i) using a radioactive label on the compound that is not immobilized, (ii) using of a fluorescent label on the non-immobilized compound, (iii) using an antibody immunospecific for the non-immobilized compound, (iv) using a label on the non- immobilized compound that excites a fluorescent support to which the immobilized compound is attached, as well as other techniques well known and routinely practiced in the art.
- the invention also provides cell-based assays to identify binding partner compounds of a nGPCR-x polypeptide.
- the invention provides a method comprising the steps of contacting a nGPCR-x polypeptide expressed on the surface of a cell with a candidate binding partner compound and detecting binding of the candidate binding partner compound to the nGPCR-x polypeptide.
- the detection comprises detecting a calcium flux or other physiological event in the cell caused by the binding of the molecule.
- Another aspect of the present invention is directed to methods of identifying compounds that bind to either nGPCR-x or nucleic acid molecules encoding nGPCR-x, comprising contacting nGPCR-x, or a nucleic acid molecule encoding the same, with a compound, and determining whether the compound binds nGPCR-x or a nucleic acid molecule encoding the same.
- Binding can be determined by binding assays which are well known to the skiled artisan, including, but not limited to, gel-shift assays, Western blots, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, ELISA, and the like, which are described in, for example, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, NY, which is incorporated herein by reference in its entirety.
- the compounds to be screened include (which may include compounds which are suspected to bind nGPCR-x, or a nucleic acid molecule encoding the same), but are not limited to, extracellular, intracellular, biologic or chemical origin.
- the methods of the invention also embrace ligands, especially neuropeptides, that are attached to a label, such as a radiolabel (e.g., 125 I, 35 S, 32 P, 33 P, 3 H), a fluorescence label, a chemiluminescent label, an enzymic label and an immunogenic label.
- a radiolabel e.g., 125 I, 35 S, 32 P, 33 P, 3 H
- fluorescence label e.g., 125 I, 35 S, 32 P, 33 P, 3 H
- Modulators falling within the scope of the invention include, but are not limited to, non-peptide molecules such as non-peptide mimetics, non-peptide allosteric effectors, and peptides.
- nGPCR-x polypeptide or polynucleotide employed in such a test may either be free in solution, attached to a solid support, borne on a cell surface or located intracellularly or associated with a portion of a cell.
- One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested.
- one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.
- nGPCR-x high throughput screening for compounds having suitable binding affinity to nGPCR-x is employed. Briefly, large numbers of different test compounds are synthesized on a solid substrate. The peptide test compounds are contacted with nGPCR-x and washed. Bound nGPCR-x is then detected by methods well known in the art. Purified polypeptides of the invention can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the protein and immobilize it on the solid support.
- an expressed nGPCR-x can be used for HTS binding assays in conjunction with its defined ligand, in this case the corresponding neuropeptide that activates it.
- the identified peptide is labeled with a suitable radioisotope, including, but not limited to, 125 1, 3 H, 35 S or 32 P, by methods that are well known to those skilled in the art.
- the peptides may be labeled by well-known methods with a suitable fluorescent derivative (Baindur et al, DrugDev. Res., 1994, 33, 373-398; Rogers, Drug Discovery Today, 1997, 2, 156-160).
- Radioactive ligand specifically bound to the receptor in membrane preparations made from the cell line expressing the recombinant protein can be detected in HTS assays in one of several standard ways, including filtration of the receptor-ligand complex to separate bound ligand from unbound ligand (Williams, Med. Res. Rev., 1991, 11, 147-184; Sweetnam et al, J. Natural Products, 1993, 56, 441-455).
- Alternative methods include a scintillation proximity assay (SPA) or a FlashPlate format in which such separation is unnecessary (Nakayama, Cur. Opinion Drug Disc. Dev., 1998, 1, 85-91 Bosse et al, J. Biomolecular Screening, 1998, 3, 285-292.).
- Binding of fluorescent ligands can be detected in various ways, including fluorescence energy transfer (FRET), direct spectrophotofluorometric analysis of bound ligand, or fluorescence polarization (Rogers, Drug Discovery Today, 1997, 2, 156-160; Hill, Cur. Opinion Drug Disc. Dev., 1998, 1, 92-97).
- FRET fluorescence energy transfer
- Differophotofluorometric analysis of bound ligand or fluorescence polarization
- assays may be used to identify specific ligands of a nGPCR-x receptor, including assays that identify ligands of the target protein through measuring direct binding of test ligands to the target protein, as well as assays that identify ligands of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods.
- binding interactions are evaluated indirectly using the yeast two- hybrid system described in Fields et al, Nature, 340:245-246 (1989), and Fieldset al, Trends in Genetics, 10:286-292 (1994), both of which are incorporated herein by reference.
- the two- hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides.
- the two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast.
- UAS upstream activation sequence
- the assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a second protein.
- the DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene.
- the second hybrid protein which contains the activation domain, cannot by itself activate expression of the reporter gene because it does not bind the UAS.
- both hybrid proteins are present, the noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of the reporter gene.
- the first protein is a GPCR gene product, or fragment thereof, that is known to interact with another protein or nucleic acid
- this assay can be used to detect agents that interfere with the binding interaction. Expression of the reporter gene is monitored as different test agents are added to the system.
- the presence of an inhibitory agent results in lack of a reporter signal.
- the yeast two-hybrid assay can also be used to identify proteins that bind to the gene product.
- a fusion polynucleotide encoding both a nGPCR-x receptor (or fragment) and a UAS binding domain i.e., a first protein
- a large number of hybrid genes each encoding a different second protein fused to an activation domain are produced and screened in the assay.
- the second protein is encoded by one or more members of a total cDNA or genomic DNA fusion library, with each second protein-coding region being fused to the activation domain.
- This system is applicable to a wide variety of proteins, and it is not even necessary to know the identity or function of the second binding protein.
- the system is highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.
- the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method that distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.
- Other embodiments of the invention comprise using competitive screening assays in which neutralizing antibodies capable of binding a polypeptide of the invention specifically compete with a test compound for binding to the polypeptide.
- the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with nGPCR-x.
- Radiolabeled competitive binding studies are described in A.H. Lin et al. Antimicrobial Agents and Chemotherapy, 1997, vol. 41, no. 10. pp. 2127-2131, the disclosure of which is incorporated herein by reference in its entirety. Identification of modulating agents
- the invention also provides methods for identifying a modulator of binding between a nGPCR-x and a nGPCR-x binding partner, comprising the steps of: (a) contacting a nGPCR-x binding partner and a composition comprising a nGPCR-x in the presence and in the absence of a putative modulator compound; (b) detecting binding between the binding partner and the nGPCR-x; and (c) identifying a putative modulator compound or a modulator compound in view of decreased or increased binding between the binding partner and the nGPCR-x in the presence of the putative modulator, as compared to binding in the absence of the putative modulator.
- compounds identified as modulating binding between nGPCR-x and a nGPCR-x binding partner may be tested in other assays including, but not limited to, in vivo models, to confirm or quantitate modulation of binding to nGPCR-x.
- nGPCR-x binding partners that stimulate nGPCR-x activity are useful as agonists in disease states or conditions characterized by insufficient nGPCR-x signaling (e.g., as a result of insufficient activity of a nGPCR-x ligand).
- nGPCR-x binding partners that block ligand- mediated nGPCR-x signaling are useful as nGPCR-x antagonists to treat disease states or conditions characterized by excessive nGPCR-x signaling.
- nGPCR-x modulators in general, as well as nGPCR-x polynucleotides and polypeptides are useful in diagnostic assays for such diseases or conditions.
- the invention provides methods for treating a disease or abnormal condition by administering to a patient in need of such treatment a substance that modulates the activity or expression of a polypeptide having sequences selected from the group consisting of SEQ ID NO: 129 to SEQ ID NO:257.
- Agents that modulate i.e., increase, decrease, or block
- nGPCR-x activity or expression may be identified by incubating a putative modulator with a cell containing a nGPCR-x polypeptide or polynucleotide and determining the effect of the putative modulator on nGPCR-x activity or expression.
- the selectivity of a compound that modulates the activity of nGPCR-x can be evaluated by comparing its effects on nGPCR-x to its effect on other GPCR compounds.
- such compounds may be further tested in other assays including, but not limited to, in vivo models, in order to confirm or quantitate their activity.
- Selective modulators may include, for example, antibodies and other proteins, peptides, or organic molecules that specifically bind to a nGPCR- x polypeptide or a nGPCR-x-encoding nucleic acid. Modulators of nGPCR-x activity will be therapeutically useful in treatment of diseases and physiological conditions in which normal or aberrant nGPCR-x activity is involved.
- nGPCR-x polynucleotides, polypeptides, and modulators may be used in the treatment of such diseases and conditions as infections, such as viral infections caused by HIV-1 or HIV-2; pain; cancers; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, etc.); Parkinson's disease; and psychotic and neurological disorder, including schizophrenia, migraine, ADHH, major depression, anxiety, mental disorder, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome, among others.
- nGPCR-x polynucleotides and polypeptides, as well as nGPCR-x modulators may also be used in diagnostic assays for such diseases or conditions.
- Methods of the invention to identify modulators include variations on any of the methods
- a modulator is identified in those instances where binding between the nGPCR-x polypeptide and the binding partner compound changes in the presence of the candidate modulator compared to binding in the absence of the candidate modulator compound.
- a modulator that increases binding between the nGPCR-x polypeptide and the binding partner compound is described as an enhancer or activator, and a modulator that decreases binding between the nGPCR-x polypeptide and the binding partner compound is described as an inhibitor.
- such compounds may be further tested in other assays including, but not limited to,in vivo models, in order to confirm or quantitate their activity as modulators.
- the invention also comprehends high-throughput screening (HTS) assays to identify compounds that interact with or inhibit biological activity (i.e., affect enzymatic activity, binding activity, etc.) of a nGPCR-x polypeptide.
- HTS assays permit screening of large numbers of compounds in an efficient manner.
- Cell-based HTS systems are contemplated to investigate nGPCR-x receptor-ligand interaction.
- HTS assays are designed to identify "hits” or "lead compounds” having the desired property, from which modifications can be designed to improve the desired property. Chemical modification of the "hit” or "lead compound” is often based on an identifiable structure/activity relationship between the "hit” and the nGPCR-x polypeptide.
- Another aspect of the present invention is directed to methods of identifying compounds which modulate (i.e., increase or decrease) an activity of nGPCR-x comprising contacting nGPCR-x with a compound, and determining whether the compound modifies activity of nGPCR-x.
- the activity in the presence of the test compared is measured to the activity in the absence of the test compound. Where the activity of the sample containing the test compound is higher than the activity in the sample lacking the test compound, the compound will have increased activity. Similarly, where the activity of the sample containing the test compound is lower than the activity in the sample lacking the test compound, the compound will have inhibited activity.
- such compounds can be further tested in other assays including, but notlimited to, in vivo models, in order to confirm or quantitate their activity.
- the present invention is particularly useful for screening compounds by using nGPCR-x in any of a variety of drug screening techniques.
- the compounds to be screened include (which may include compounds which are suspected to modulate nGPCR-x activity), but are not limited to, extracellular, intracellular, biologic or chemical origin.
- the nGPCR-x polypeptide employed in such a test may be in any form, preferably, free in solutbn, attached to a solid support, borne on a cell surface or located intracellularly.
- One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.
- the activity of nGPCR-x polypeptides of the invention can be determined by, for example, examining the ability to bind or be activated by chemically synthesized peptide ligands.
- the activity of nGPCR-x polypeptides can be assayed by examining their ability to bind calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and photons.
- the activity of the nGPCR-x polypeptides can be determined by examining the activity of effector molecules including, but not limited to, adenylate cyclase, phospholipases and ion channels.
- modulators of nGPCR-x polypeptide activity may alter a GPCR receptor function, such as a binding property of a receptor or an activity such as G protein-mediated signal transduction or membrane localization.
- the assay may take the form of an ion flux assay, a yeast growth assay, a non-hydrolyzable GTP assay such as a [ 3 ⁇ ]-GTP ⁇ S assay, a cAMP assay, an inositol triphosphate assay, a diacylglycerol assay, an Aequorin assay, a Luciferase assay, a FLIPR assay for intracellular Ca 2" * " concentration, a mitogenesis assay, a MAP Kinase activity assay, an arachidonic acid release assay (e.g., using fHJ-arachidonic acid), and an assay for extracellular acidification rates, as well as other binding or function-based assays of n
- the invention comprehends the inclusion of any of the G proteins known in the art, such as G 16 , G 15, or chimeric G q d5 , G qS 5, G q05 , G q2 5, and the like.
- nGPCRx activity can be determined by methodologies that are used to assay for FaRP activity, which is well known to those skilled in the art.
- Biological activities of nGPCR-x receptors according to the invention include, but are not limited to, the binding of a natural or an unnatural ligand, as well as any one of the functional activities of GPCRs known in the art.
- Non-limiting examples of GPCR activities include transmembrane signaling of various forms, which may involve G protein association and/or the exertion of an influence over G protein binding of various guan ⁇ ylate nucleotides; another exemplary activity of GPCRs is the binding of accessory proteins or polypeptides that differ from known G proteins.
- the modulators of the invention exhibit a variety of chemical structures, which can be generally grouped into non-peptide mimetics of natural GPCR receptor ligands, peptide and non-peptide allosteric effectors of GPCR receptors, and peptides that may function as activators or inhibitors (competitive, uncompetitive and non-competitive) (e.g., antibody products) of GPCR receptors.
- the invention does not restrict the sources for suitable modulators, which may be obtained from natural sources such as plant, animal or mineral extracts, or nortnatural sources such as small molecule libraries, including the products of combinatorial chemical approaches to library construction, and peptide libraries.
- Examples of peptide modulators of GPCR receptors exhibit the following primary structures: GLGPRPLRFamide, GNSFLRFamide, GGPQGPLRFamide, GPSGPLRFamide, PDVDHVFLRFamide, and pyro- EDVDHVFLRFamide.
- Recombinant receptors are preferred for binding assay HTS because they allow for better specificity (higher relative purity), provide the ability to generate large amounts of receptor material, and can be used in a broad variety of formats (see Hodgson, Bio/Technology, 1992, 10, 973-980; each of which is incorporated herein by reference in its entirety).
- heterologous systems are available for functional expression of recombinant receptors that are well known to those skilled in the art.
- Such systems include bacteria (Strosberg, et al, Trends in Pharmacological Sciences, 1992, 13, 95-98), yeast (Pausch, Trends in Biotechnology, 1997, 15, 487-494), several kinds of insect cells (Vanden Broeck, Irt. Rev. Cytology, 1996, 164, 189-268), amphibian cells (Jayawickreme et al, Current Opinion in Biotechnology, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK-293, COS, etc.; see Gerhardt, et al, Bur. J.
- methods of screening for compounds that modulate nGPCR-x activity comprise contacting test compounds with nGPCR-x and assaying for the presence of a complex between the compound and nGPCR-x.
- the ligand is typically labeled. After suitable incubation, free ligand is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular compound to bind to nGPCR-x.
- the G proteins required for functional expression of heterologous GPCRs can be native constituents of the host cell or can be introduced through well-known recombinant technology.
- the G proteins can be intact or chimeric.
- a nearly universally competent G protein e.g., G ⁇ i ⁇
- G protein activation results in the stimulation or inhibition of other native proteins, events that can be linked to a measurable response.
- Examples of such biological responses include, but are not limited to, the following: the ability to survive in the absence of a limiting nutrient in specifically engineered yeast cells (Pausch, Trends in Biotechnology, 1997, 15, 487-494); changes in intracellular Ca 2+ concentration as measured by fluorescent dyes (Murphy, et al, Cur. Opinion Drug Disc. Dev., 1998, 1, 192-199). Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH; an automated system suitable for HTS has been described for these purposes (Schroeder, et al, J. Biomolecular Screening, 1996, 1, 75-80).
- Preferred methods of HTS employing these receptors include permanently transfected
- CHO cells in which agonists and antagonists can be identified by the ability to specifically alter the binding of GTP ⁇ [ 35 S] in membranes prepared from these cells.
- permanently transfected CHO cells could be used for the preparation of membranes which contain significant amounts of the recombinant receptor proteins; these membrane preparations would then be used in receptor binding assays, employing the radiolabeled ligand specific for the particular receptor.
- a functional assay such as fluorescent monitoring of ligand-induced changes in internal Ca 2+ concentration or membrane potential in permanently transfected CHO cells containing each of these receptors individually or in combination would be preferred for HTS.
- Equally preferred would be an alternative type of mammalian cell, such as HEK-293 or COS cells, in similar formats. More preferred would be permanently transfected insect cell lines, such asDrosophila S2 cells. Even more preferred would be recombinant yeast cells expressing the Drosophila melanogaster receptors in HTS formats well known to those skilled in the art (e.g., Pausch,7re.?J,s in'Biotechnology, 1997, 15, 487-494).
- the invention contemplates a multitude of assays to screen and identify inhibitors of ligand binding to nGPCR-x receptors.
- the nGPCR-x receptor is immobilized and interaction with a binding partner is assessed in the presence and absence of a candidate modulator such as an inhibitor compound.
- interaction between the nGPCR- x receptor and its binding partner is assessed in a solution assay, both in the presence and absence of a candidate inhibitor compound.
- an inhibitor is identified as a compound that decreases binding between the nGPCR-x receptor and its binding partner.
- Another contemplated assay involves a variation of the dihybrid assay wherein an inhibitor of protein/protein interactions is identified by detection of a positive signal in a transformed or transfected host cell, as described in PCT publication number WO 95/20652, published August 3, 1995.
- Candidate modulators contemplated by the invention include compounds selected from libraries of either potential activators or potential inhibitors. There are a number of different libraries used for the identification of small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of random chemical structures, some of which are analogs of known compounds or analogs of compounds that have been identified as "hits" or "leads" in other drug discovery screens, some of which are derived from natural products, and some of which arise from non-directed synthetic organic chemistry.
- Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see Science 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. These libraries are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are non-peptide combinatorial libraries.
- Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries.
- combinatorial chemistry and libraries created therefrom see Myers, Curr. Opin. Biotechnol. 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit” (or “lead") to optimize the capacity of the "hit" to modulate activity.
- binding partner as used herein broadly encompasses non-peptide modulators, as well as such peptide modulators as neuropeptides other than natural ligands, antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified nGPCR-x gene.
- polypeptides of the invention are employed as a research tool for identification, characterization and purification of interacting, regulatory proteins.
- Appropriate labels are incorporated into the polypeptides of the invention by various methods known in the art and the polypeptides are used to capture interacting molecules. For example, molecules are incubated with the labeled polypeptides, washed to remove unbound polypeptides, and the polypeptide complex is quantified. Data obtained using different concentrations of polypeptide are used to calculate values for the number, affinity, and association of polypeptide with the protein complex.
- Labeled polypeptides are also useful as reagents for the purification of molecules with which the polypeptide interacts including, but not limited to, inhibitors.
- affinity purification a polypeptide is covalently coupled to a chromatography column. Cells and their membranes are extracted, and various cellular subcomponents are passed over the column. Molecules bind to the column by virtue of their affinity to the polypeptide. The polypeptide-complex is recovered from the column, dissociated and the recovered molecule is subjected to protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotides for cloning the corresponding gene from an appropriate cDNA library.
- compounds may be identified which exhibit similar properties to the ligand for the nGPCR-x of the invention, but which are smaller and exhibit a longer half time than the endogenous ligand in a human or animal body.
- a molecule according to the invention is used as a "lead” compound.
- the design of mimetics to known pharmaceutically active compounds is a well-known approach in the development of pharmaceuticals based on such "lead” compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number ofmolecules for a target property.
- structural data deriving from the analysis of the deduced amino acid sequences encoded by the DNAs of the present invention are useful to design new drugs, more specific and therefore with a higher pharmacological potency.
- the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a composition or pharmaceutical composition can be prepared thereof for oral intake, such as in tablets.
- a composition or pharmaceutical composition comprising the nucleic acid molecules, vectors, polypeptides, antibodies and compounds identified by the screening methods described herein, can be prepared for any route of administration including, but not limited to, oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal.
- the nature of the carrier or other ingredients will depend on the specific route of administration and particular embodiment of the invention to be administered. Examples of techniques and protocols that are useful in this context are, inter alia, found in Remington's Pharmaceutical Sciences, 16 th edition, Osol, A (ed.), 1980, which is incorporated herein by reference in its entirety.
- the dosage of these low molecular weight compounds will depend on the disease state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound.
- For treating human or animals between approximately 0.5 mg/kg of body weight to 500 mg/kg of body weight of the compound can be administered. Therapy is typically administered at lower dosages and is continued until the desired therapeutic outcome is observed.
- the present compounds and methods including nucleic acid molecules, polypeptides, antibodies, compounds identified by the screening methods described herein, have a variety of pharmaceutical applications and may be used, for example, to treat or prevent unregulated cellular growth, such as cancer cell and tumor growth. In a particular embodiment, the present molecules are used in gene therapy.
- gene therapy procedures seee.g. Anderson, Science, 1992, 256, 808-813, which is incorporated herein by reference in its entirety.
- the present invention also encompasses a method of agonizing (stimulating) or antagonizing a nGPCR-x natural binding partner associated activity in a mammal comprising administering to said mammal an agonist or antagonist to one of the above disclosed polypeptides in an amount sufficient to effect said agonism or antagonism.
- One embodiment of the present invention is a method of treating diseases in a mammal with an agonist or antagonist of the protein of the present invention comprises administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize nGPCR-x-associated functions.
- Exemplary diseases and conditions amenable to treatment based on the present invention include, but are not limited to, thyroid disorders (e.g. thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (e.g., Chron's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes
- the proper dosage depends on various factors such as the type of disease being treated, the particular composition being used and the size and physiological condition of the patient.
- Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially takes into account the IC 50 as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.
- Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder.
- Such measurements can be carried out.
- HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI.
- Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.
- Toxicity studies can also be carried out by measuring the blood cell composition.
- toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.
- the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day.
- Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness. Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.
- nGPCR-x mRNA transcripts may found in many other tissues, including, but not limited to peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues.
- nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla.
- Sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128 will, as detailed above, enable screening the endogenous neurotransmitters/hormones/ligands which activate, agonize, or antagonize nGPCR-x and for compounds with potential utility in treating disorders including, but not limited to, thyroid disorders (e.g.
- thyreotoxicosis myxoedema
- renal failure inflammatory conditions (e.g., Chron's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including schizophrenia, migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc.); infections, such as viral infections caused by HIN-1 or HIN-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardi
- nGPCR-x may be useful in the treatment of respiratory ailments such as asthma, where T cells are implicated by the disease. Contraction of airway smooth muscle is stimulated by thrombm. Cicala et al (1999) Br J Pharmacol 126:478-484. Additionally, in bronchiolitis obliterans, it has been noted that activation of thrombin receptors may be deleterious. Hauck et al. (1999) Am J Physiol 277:L22-L29. Furthermore, mast cells have also been shown to have thrombin receptors. Cirinoet al (1996) J Exp Med 183:821-827.
- nGPCR-x may also be useful in remodeling of airway structure s in chronic pulmonary inflammation via stimulation of fibroblast procollagen synthesis. See, e.g., Chambers et al. (1998) Biochem J 333:121-127; Trejo et al. (1996) J Biol Chem 271:21536-21541.
- nGPCR-x may be useful in the treatment of unstable angina due to the role of T cells and inflammation. See Aukrust et al. (1999) Circulation 100:614-620.
- a further example is the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and thyroiditis. Due to the tissue expression profile of nGPCR-x, inhibition of thrombin receptors may be beneficial for these diseases. See, e.g., Morris et al. (1996) Ann Rlieum Di; 55:841-843. In addition to T cells, NK cells and monocytes are also critical cell types which contribute to the pathogenesis of these diseases.
- nGPCR-x in bone marrow and spleen may suggest that it may play a role in the proliferation of hematopoietic progenitor cells. See DiCuccio et al. (1996) Exp Hematol 24:914-918.
- nGPCR-x may be useful in the treatment of acute and/or traumatic brain injury.
- Astrocytes have been demonstrated to express thrombin receptors. Activation of thrombin receptors may be involved in astroghosis following brain injury. Therefore, inhibition of receptor activity may be beneficial for limiting neuroinflammation.
- Scar formation mediated by astrocytes may also be limited by inhibiting thrombin receptors. See, e.g, Pindon et al. (1998) Eur J Biochem 255:766-774; Ubl & Reiser. (1997) Glia 21:361-369; Grabham & Cunningham (1995) J Neurochem 64:583-591.
- nGPCR-x receptor activation may mediate neuronal and astrocyte apoptosis and prevention of neurite outgrowth. Inhibition would be beneficial in both chronic and acute brain injury. See, e.g., Donovan et al. (1997) J Neurosci 17:5316-5326; Turgeon et al (1998) J Neurosci 18:6882-6891; Smith-Swintosky et al. (1997) J Neurochem 69:1890-1896; Gill et al. (1998) Brain Res 797:321-327; Suidan et al (1996) Semin Thromb Hemost 22:125-133. [000209] The attached Sequence Listing contains the sequences of the polynucleotides and polypeptides of the invention and is incorporated herein by reference in its entirety. Methods of Screening Human Subjects
- the invention provides genetic screening procedures that entail analyzing a person's genome ⁇ in particular their alleles for the nGPCR-x of the invention — to determine whether the individual possesses a genetic characteristic found in other individuals that are considered to be afflicted with, or at risk for, developing a mental disorder or disease of the brain that is suspected of having a hereditary component.
- the invention provides a method for determining a potential for developing a disorder affecting the brain in a human subject comprising the steps of analyzing the coding sequence of one or more nGPCR-x genes from the human subject; and determining development potential for the disorder in said human subject from the analyzing step.
- the invention provides a method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of: (a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering the amino acid sequence, expression, or biological activity of at least one seven transmembrane receptor that is expressed in the brain, wherein the seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or an allelic variant thereof, and wherein the nucleic acid corresponds to the gene encoding the seven transmembrane receptor; and (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity, of allele in the nucleic acid correlates with an increased risk of developing the disorder.
- human subject is meant any human being, human embryo, or human fetus. It will be apparent that methods of the present invention will be of particular interest to individuals that have themselves been diagnosed with a disorder affecting the brain or have relatives that have been diagnosed with a disorder affecting the brain.
- screening for an increased risk determination of whether a genetic variation exists in the human subject that correlates with a greater likelihood of developing a disorder affecting the brain than exists for the human population as a whole, or for a relevant racial or ethnic human sub-population to which the individual belongs. Both positive and negative determinations (i.e., determinations that a genetic predisposition marker is present or is absent) are intended to fall within the scope of screening methods of the invention.
- the presence of a mutation altering the sequence or expression of at least one nGPCR-x seven transmembrane receptor allele in the nucleic acid is correlated with an increased risk of developing mental disorder, whereas the absence of such a mutation is reported as a negative determination.
- the "assaying" step of the invention may involve any techniques available for analyzing nucleic acid to determine its characteristics, including but not limited to well-known techniques such as single-strand conformation polymorphism analysis (SSCP) [Orita et al, Proc Natl. Acad. Sci. USA, 86: 2766-2770 (1989)]; heteroduplex analysis [Whiteet /., Genomics, 12: 301- 306 (1992)]; denaturing gradient gel electrophoresis analysis [Fischer et al, Proc. Natl. Acad. Sci.
- SSCP single-strand conformation polymorphism analysis
- the assaying step comprises at least one procedure selected from the group consisting of: (a) determining a nucleotide sequence of at least one codon of at least one nGPCRx allele of the human subject; (b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; (c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and (d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.
- the assaying involves sequencing of nucleic acid to determine nucleotide sequence thereof, using any available sequencing technique.
- any available sequencing technique See, e.g., Sanger et al, Proc. Natl. Acad. Sci. (USA), 74: 5463-5467 (1977) (dideoxy chain termination method); Mirzabekov, TIBTECH, 12: 27-32 (1994) (sequencing by hybridization); Drmanac et al, Nature Biotechnology, 16: 54-58 (1998); U.S. Patent No.
- the analysis may entail sequencing of the entire nGPCR gene genomic DNA sequence, or portions thereof; or sequencing of the entire seven transmembrane receptor coding sequence or portions thereof. In some circumstances, the analysis may involve a determination of whether an individual possesses a particular allelic variant, in which case sequencing of only a small portion of nucleic acid —enough to determine the sequence of a particular codon characterizing the allelic variant — is sufficient.
- This approach is appropriate, for example, when assaying to determine whether one family member inherited the same allelic variant that has been previously characterized for another family member, or, more generally, whether a person's genome contains an allelic variant that has been previously characterized and correlated with a mental disorder having a heritable component.
- the assaying step comprises performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.
- the hybridization involves a determination of whether nucleic acid derived from the human subject will hybridize with one or more oligonucleotides, wherein the oligonucleotides have nucleotide sequences that correspond identically to a portion of the nGPCR-x gene sequence taught herein, or that correspond identically except for one mismatch.
- the hybridization conditions are selected to differentiate between perfect sequence complementarity and imperfect matches differing by one or more bases.
- Such hybridization experiments thereby can provide single nucleotide polymorphism sequence information about the nucleic acid from the human subject, by virtue of knowing the sequences of the oligonucleotides used in the experiments.
- Several of the techniques outlined above involve an analysis wherein one performs a polynucleotide migration assay, e.g., on a polyacrylamide electrophoresis gel (or in a capillary electrophoresis system), under denaturing or non-denaturing conditions.
- Nucleic acid derived from the human subject is subjected to gel electrophoresis, usually adjacent to (or co-loaded with) one or more reference nucleic acids, such as reference GPCR-x encoding sequences having a coding sequence identical to all or a portion of SEQ ID NOS: 1 to 110 (or identical except for one known polymorphism).
- nucleic acid from the human subject and the reference sequence(s) are subjected to similar chemical or enzymatic treatments and then electrophoresed under conditions whereby the polynucleotides will show a differential migration pattern, unless they contain identical sequences.
- nucleic acid of a human subject is intended to include nucleic acid obtained directly from the human subject (e.g., DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample); and also nucleic acid derived from nucleic acid obtained directly from the human subject.
- nucleic acid obtained directly from the human subject e.g., DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample
- nucleic acid derived from nucleic acid obtained directly from the human subject e.g., DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample
- PCR polymerase chain reaction
- the term "mutation” includes addition, deletion, and/or substitution of one or more nucleotides in the GPCR gene sequence (e.g., ascompared to the seven transmembrane receptor-encoding sequences set forth of SEQ ID NO:l to SEQ ID NO: 128, and other polymorphisms that occur in introns (where introns exist) and that are identifiable via sequencing, restriction fragment length polymorphism, or other techniques.
- the various activity examples provided herein permit determination of whether a mutation modulates activity of the relevant receptor in the presence or absence of various test substances.
- the invention provides methods of screening a person's genotype with respect to the nGPCR-x of the invention, and correlating such genotypes with diagnoses for disease or with predisposition for disease (for genetic counseling).
- the invention provides a method of screening for an nGPCR-x hereditary mental disorder genotype in a human patient, comprising the steps of: (a) providing a biological sample comprising nucleic acid from the patient, the nucleic acid including sequences corresponding to said patient's nGPCR-x alleles; (b) analyzing the nucleic acid for the presence of a mutation or mutations; (c) determining a nGPCR-x genotype from the analyzing step; and (d) correlating the presence of a mutation in an nGPCR-x allele with a hereditary mental disorder genotype.
- the biological sample is a cell sample containing human cells that contain genomic DNA of the human subject.
- the analyzing can be performed analogously to the assaying described in preceding paragraphs.
- the analyzing comprises sequencing a portion of the nucleic acid (e.g., DNA or RNA), the portion comprising at least one codon of the nGPCR-x alleles.
- the invention also may be practiced by assaying one or more proteins of a human subject to determine the presence or absence of an amino acid sequence variation in GPCR protein from the human subject.
- Such protein analyses may be performed, e.g., by fragmenting GPCR protein via chemical or enzymatic methods and sequencing the resultant peptides; or by Western analyses using an antibody having specificity for a particular allelic variant of the GPCR.
- the invention also provides materials that are useful for performing methods of the invention.
- the present invention provides oligonucleotides useful as probes in the many analyzing techniques described above.
- oligonucleotide probes comprise 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides that have a sequence that is identical, or exactly complementary, to a portion of a human GPCR gene sequence taught herein (or allelic variant thereof), or that is identical or exactly complementary except for one nucleotide substitution.
- the oligonucleotides have a sequence that corresponds in the foregoing manner to a human GPCR coding sequence taught herein, and in particular, the coding sequences set forth in SEQ ID NO:l to SEQ ID NO: 128.
- an oligonucleotide probe of the invention is purified and isolated.
- the oligonucleotide probe is labeled, e.g., with a radioisotope, chromophore, or fluorophore.
- the probe is covalently attached to a solid support. [See generally Ausubel et al. and Sambrook et al, supra.]
- kits comprising reagents that are useful for practicing methods of the invention.
- the invention provides a kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association: (a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-x seven transmembrane receptor gene, the oligonucleotide comprising 6-50 nucleotides that have a sequence that is identical or exactly complementary to a portion of a human nGPCR-x gene sequence or nGPCR-x coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and (b) a media packaged with the oligonucleotide containing information identifying polymorphisms identifiable with the probe that correlate with mental disorder or a genetic predisposition therefor.
- Exemplary information-containing media include printed paper package inserts or packaging labels; and magnetic and optical storage media that are readable by computers or machines used by practitioners who perform genetic screening and counseling services. The practitioner uses the information provided in the media to correlate the results of the analysis with the oligonucleotide with a diagnosis. In a preferred variation, the oligonucleotide is labeled.
- the invention provides methods of identifying those allelic variants of GPCRs of the invention that correlate with mental disorders.
- the invention provides a method of identifying a seven transmembrane allelic variant that correlates with a mental disorder, comprising steps of: (a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny; (b) analyzing the nucleic acid for the presence of a mutation or mutations in at least one seven transmembrane receptor that is expressed in the brain, wherein the at least one seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding the at least one seven transmembrane receptor; (c) determining a genotype for the patient for the at least one seven transmembrane receptor from said
- chromosomal localization data facilitates identifying an involved nGPCR with a chromosomal marker.
- the foregoing method can be performed to correlate the nGPCR-x of the invention to a number of disorders having hereditary components that are causative or that predispose persons to the disorder.
- the disorder is a mental disorder.
- polynucleotides that comprise the allelic variant sequences identified by such methods, and polypeptides encoded by the allelic variant sequences, and oligonucleotide and oligopeptide fragments thereof that embody the mutations that have been identified.
- Such materials are useful in in vitro cell ⁇ ree and cell-based assays for identifying lead compounds and therapeutics for treatment of the disorders.
- the variants are used in activity assays, binding assays, and assays to screen for activity modulators described herein.
- the invention provides a purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-x receptor allelic variant identified according to the methods described above; and an oligonucleotide that comprises the sequences that differentiate the allelic variant from the nGPCR-x sequences set forth in SEQ ID NO:l to SEQ ID NO: 128.
- the invention also provides a vector comprising the polynucleotide (preferably an expression vector); and a host cell transformed or transfected with the polynucleotide or vector.
- the invention also provides an isolated cell line that is expressing the allelic variant nGPCR-x polypeptide; purified cell membranes from such cells; purified polypeptide; and synthetic peptides that embody the allelic variation amino acid sequence.
- the invention provides a purified polynucleotide comprising a nucleotide sequence encoding a nGPCR-x seven transmembrane receptor protein of a human that is affected with a mental disorder; wherein said polynucleotide hybridizes to the complement of a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128 under the following hybridization conditions: (a) hybridization for 16 hours at 42 °C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising O.lx SSC and 1% SDS; and wherein the polynucleot
- An exemplary assay for using the allelic variants is a method for identifying a modulator of nGPCR-x biological activity, comprising the steps of: (a) contacting a cell expressing the allelic variant in the presence and in the absence of a putative modulator compound; (b) measuring nGPCR-x biological activity in the cell; and (c) identifying a putative modulator compound in view of decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator.
- Examples 1 and 2 are actual while the remaining Examples are prophetic. Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that also are intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of fee invention.
- the Celera database was searched using known GPCR receptors as query sequences to find patterns suggestive of novel G protein-coupled receptors. Positive hits were further analyzed with the GCG program BLAST to determine which ones were the most likely candidates to encode G protein-coupled receptors, using the standard (default) alignment produced by BLAST as a guide.
- BLAST algorithm which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul et al, J. Mol. Biol., 1990, 215, 403-410, which is incorporated herein by reference in its entirety).
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
- HSPs high scoring sequence pair
- T is referred to as the neighborhood word score threshold (Altfflet al, supra).
- initial neighborhood word hits act as seeds for initiating searchesto find HSPs containing them.
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached.
- the Blast algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm Kerlin et al, Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety
- Gapped BLAST perform a statistical analysis of the similarity between two sequences.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- a nucleic acid is considered similar to a GPCR gene or cDNA if the smallest sum probability in comparison of the test nucleic acid to a GPCR nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- Homology searches are performed with the program BLAST version 2.08.
- a collection of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search.
- the amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.
- Multiple query sequences may have a significant alignment to the same genomic region, although each alignment may not cover exactly the same DNA region.
- a procedure is used to determine the region of maximum common overlap between the alignments from several query sequences. This region is called the consensus DNA region.
- the procedure for determining this consensus involves the automatic parsing of the BLAST output files using the program MSPcrunch to produce a tabular report. From this tabular report the start and end of each alignment in the genomic DNA is extracted. This information is used by a PERL script to derive the maximum common overlap. These regions are reported in the form of a unique sequence identifier, a start and the end position in the sequence. The sequences defined by these regions were extracted from the original genomic sequence file using the program fetchdb.
- nGPRCR-x cDNAs were sequenced directly using an ABI377 fluorescence-based sequencer (Perkin-Elmer/ Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISMTM Ready Dye-Deoxy Terminator kit with Taq FSTM polymerase.
- Each ABI cycle sequencing reaction contained about 0.5 ⁇ g of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 minute, followed by 50 cycles using the following parameters: 98°C for 30 seconds, annealing at 50°C for 30 seconds, and extension a 60°C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler.
- Extension products were purified using CentriflexTM gel filtration cartridges (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 xg for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 5 ⁇ l of a DNA loading solution (83% deionized formamide, 8.3mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for three minutes and loaded into the gel sample wells for sequence analysis using the ABI377 sequencer.
- a DNA loading solution 83% deionized formamide, 8.3mM EDTA, and 1.6 mg/ml Blue Dextran
- Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp were obtained. Potential sequencing errors were minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers annealing at different locations until all sequencing ambiguities were removed.
- Table 5 contains the sequences of the polynucleotides and polypeptides of the invention. The transmembrane domains within the polypeptide sequence are identified by underlining.
- amino acid sequence ⁇ SEQ ID NO. 129> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 1:
- the following amino acid sequence ⁇ SEQ ID NO. 130> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 2:
- amino acid sequence ⁇ SEQ ID NO. 131> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 3:
- the following amino acid sequence ⁇ SEQ ID NO. 132> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 4: QIDYSSIKNCQKHEGPKGETDIGALVVVEVQGLSPDCSASSHSS PSR APSFPRSPGFSVTYSEKYCP AELNASSSTYLLGPFIFLP ASFHLHHLVTSCLLYVFLYLLPSYILKALFFLKQILTFLLILNM LFSAWK TILKLTHPQK FKNH RIQ KSEPS ER GKGTPFNVSTIA
- amino acid sequence ⁇ SEQ ID NO. 133> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 5:
- amino acid sequence ⁇ SEQ ID NO. 134> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 6:
- amino acid sequence ⁇ SEQ ID NO. 135> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 7:
- amino acid sequence ⁇ SEQ ID NO. 136> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 8:
- amino acid sequence ⁇ SEQ ID NO. 137> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 9:
- amino acid sequence ⁇ SEQ ID NO. 138> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 10:
- amino acid sequence ⁇ SEQ ID NO. 139> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 11:
- the following amino acid sequence ⁇ SEQ ID NO. 140> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 12:
- amino acid sequence ⁇ SEQ ID NO. 141> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 13:
- amino acid sequence ⁇ SEQ ID NO. 142> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 14:
- amino acid sequence ⁇ SEQ ID NO. 143> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 15:
- amino acid sequence ⁇ SEQ ID NO. 144> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 16:
- amino acid sequence ⁇ SEQ ID NO. 145> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 17:
- amino acid sequence ⁇ SEQ ID NO. 146> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 18:
- amino acid sequence ⁇ SEQ ID NO. 147> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 19:
- amino acid sequence ⁇ SEQ ID NO. 148> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 20:
- amino acid sequence ⁇ SEQ ID NO. 149> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 21:
- the following amino acid sequence ⁇ SEQ ID NO. 150> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO.22:
- amino acid sequence ⁇ SEQ ID NO. 151> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 23:
- amino acid sequence ⁇ SEQ ID NO. 152> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 24:
- amino acid sequence ⁇ SEQ ID NO. 153> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 25:
- amino acid sequence ⁇ SEQ ID NO. 154> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 26:
- amino acid sequence ⁇ SEQ ID NO. 155> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 27:
- amino acid sequence ⁇ SEQ ID NO. 156> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 28:
- amino acid sequence ⁇ SEQ ID NO. 157> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 29:
- amino acid sequence ⁇ SEQ ID NO. 158> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 30:
- the following amino acid sequence ⁇ SEQ ID NO. 159> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 31:
- the following amino acid sequence ⁇ SEQ ID NO. 160> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 32:
- amino acid sequence ⁇ SEQ ID NO. 161> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 33:
- amino acid sequence ⁇ SEQ ID NO. 162> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 34:
- amino acid sequence ⁇ SEQ ID NO. 163> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 35:
- the following amino acid sequence ⁇ SEQ ID NO. 164> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 36: GLIEWNLEAGRTGEGLPVFASKVIFSYLCEVLRNY NHPSYYKRDQDQQHFLKHRVGHDKCPRRDDTREES GVNLSVLTHYFISNLLASKIVFFFCESLSSFPIJFTNNSYPQSLCLPIGCFLSKFHI-GLLLPPSRTLKSQSY LIGSLNALCIFLVTTHNNYNDKQKNFISVSLGEDGWMEPQKYARITKHNLN
- amino acid sequence ⁇ SEQ ID NO. 165> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 37:
- amino acid sequence ⁇ SEQ ID NO. 166> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 38:
- amino acid sequence ⁇ SEQ ID NO. 167> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 39:
- amino acid sequence ⁇ SEQ ID NO. 168> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 40:
- amino acid sequence ⁇ EQ ID NO. 169> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 41:
- amino acid sequence ⁇ SEQ ID NO. 170> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 42:
- amino acid sequence ⁇ SEQ ID NO. 171> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 43:
- amino acid sequence ⁇ SEQ ID NO. 172> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 44:
- amino acid sequence ⁇ SEQ ID NO. 173> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO.45:
- amino acid sequence ⁇ SEQ ID NO. 175> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 47:
- amino acid sequence ⁇ SEQ ID NO. 176> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 48:
- amino acid sequence ⁇ SEQ ID NO. 177> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 49:
- amino acid sequence ⁇ SEQ ID NO. 178> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 50:
- amino acid sequence ⁇ SEQ ID NO. 179> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 51:
- the following amino acid sequence ⁇ SEQ ID NO. 180> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 52:
- amino acid sequence ⁇ SEQ ID NO. 181> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 53:
- amino acid sequence ⁇ SEQ ID NO. 182> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 54:
- amino acid sequence ⁇ SEQ ID NO. 183> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 55:
- amino acid sequence ⁇ SEQ ID NO. 184> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 56:
- amino acid sequence ⁇ SEQ ID NO. 185> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 57:
- amino acid sequence ⁇ SEQ ID NO. 186> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 58:
- amino acid sequence ⁇ SEQ ID NO. 188> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 60:
- amino acid sequence ⁇ SEQ ID NO. 189> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 61:
- the following amino ' acid sequence ⁇ SEQ ID NO. 190> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 62: ISPEPTKRDKHSVVFFSALIQLCCKFLFSEETPRSMTEIFFPFPFCDVHLSILDACTPELTSHSEHAQHHT LPSSPARTVHSSSCVNPWLSFLFRTAFQAPWTLTLTSYAQKRLWETEVTISGFRMAFFCSRKEPAVPQVLF LVPYSSAPLRIKEVGTVSSLYSYIIESNYFCNLLSSSGYYMNEHSVPFIDLLSGYILAFNILYLLHYLGL
- amino acid sequence ⁇ SEQ ID NO. 191> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 63:
- amino acid sequence ⁇ SEQ ID NO. 192> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 64:
- amino acid sequence ⁇ SEQ ID NO. 193> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 65:
- amino acid sequence ⁇ SEQ ID NO. 194> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 66:
- amino acid sequence ⁇ SEQ ID NO. 195> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 67:
- amino acid sequence ⁇ SEQ ID NO. 196> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 68:
- amino acid sequence ⁇ SEQ ID NO . 197> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO . 69 :
- amino acid sequence ⁇ SEQ ID NO. 198> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 70:
- amino acid sequence ⁇ SEQ ID NO. 199> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO: 71:
- amino acid sequence ⁇ SEQ ID NO. 201> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 73:
- amino acid sequence ⁇ SEQ ID NO. 202> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 74:
- amino acid sequence ⁇ SEQ ID NO. 203> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 75:
- amino acid sequence ⁇ SEQ ID NO. 204> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 76:
- amino acid sequence ⁇ SEQ ID NO. 205> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 77:
- amino acid sequence ⁇ SEQ ID NO. 206> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 78:
- the following amino acid sequence ⁇ SEQ ID NO. 207> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 79:
- amino acid sequence ⁇ SEQ ID NO. 208> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 80:
- amino acid sequence ⁇ SEQ ID NO. 209> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 81:
- amino acid sequence ⁇ SEQ ID NO. 210> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 82:
- amino acid sequence ⁇ SEQ ID NO. 211> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 83:
- amino acid sequence ⁇ SEQ ID NO. 212> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 84:
- amino acid sequence ⁇ SEQ ID NO. 213> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 85:
- amino acid sequence ⁇ SEQ ID NO. 214> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 86:
- amino acid sequence ⁇ SEQ ID NO. 215> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 87:
- amino acid sequence ⁇ SEQ ID NO. 216> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 88:
- amino acid sequence ⁇ SEQ ID NO. 217> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 89:
- SSFVSFSF WLLAII-GVPWLVDTSPQSLLLSSHGHLPYVSVFFPVSYKTSVIRFKAHPIHDDLISRSLSLC LQSSFSKGHNLKFVNVSLGARR LFNLLKTTYLVFRILKHASVCMYIVRWIYRSYYLVLTKLIFTKYTSGS KNFRQKHPTYTQQSHKPKRIGKLKGLLSHPLYKLFVSHKLPHNHT
- amino acid sequence ⁇ SEQ ID NO. 218> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 90:
- amino acid sequence ⁇ SEQ ID NO. 219> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 91:
- amino acid sequence ⁇ SEQ ID NO. 220> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO.92:
- amino acid sequence ⁇ SEQ ID NO. 221> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 93:
- amino acid sequence ⁇ SEQ ID NO. 222> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 94:
- amino acid sequence ⁇ SEQ ID NO. 223> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 95:
- amino acid sequence ⁇ SEQ ID NO. 224> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 96:
- amino acid sequence ⁇ SEQ ID N0.225> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 97:
- amino acid sequence ⁇ SEQ ID NO. 226> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 98:
- amino acid sequence ⁇ SEQ ID NO. 227> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO.99:
- the following amino acid sequence ⁇ SEQ ID NO. 228> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 100:
- the following amino acid sequence ⁇ SEQ ID NO. 229> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 101:
- amino acid sequence ⁇ SEQ ID NO. 230 is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 102:
- the following amino acid sequence ⁇ SEQ ID NO. 231> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 103:
- amino acid sequence ⁇ SEQ ID NO. 232> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 104:
- the following amino acid sequence ⁇ SEQ ID NO. 233> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 105: KAFLKILLAGTCYREDSIHKLTKYFPSYIFIFINSFLNDIYFWVFTHVLYMFLFSFTIEHTLYQPEASEHL MGAKNKKKTSFGIANTFHLCLIHIKFESWAYYFEHFH
- amino acid sequence ⁇ SEQ ID NO. 234> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 106:
- the following amino acid sequence ⁇ SEQ ID NO. 235> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 107: TA DPSIFGVVGNLVAIVVLCKSRKEQKETTFYTVMRLAATDLLFTLLVSQVTIAMYMKGGPGGQLLCEY SIFSLFFFSQSGLSIVCAMISIQVICVRHSKSFKSFMF
- amino acid sequence ⁇ SEQ ID NO. 236> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 108:
- amino acid sequence ⁇ SEQ ID NO. 237> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 109:
- amino acid sequence ⁇ SEQ ID NO. 238> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 110:
- amino acid sequence ⁇ SEQ ID NO. 239> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. Ill:
- the following amino acid sequence ⁇ SEQ ID NO. 240> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 112: CNYSTHQLYHFNSLYIVPQVSFSNGHYGLSTKYPFSPFPLILETDLFSYLTFPSLSLCLGGSSNPVSAMC FIVQGYFICHDNNWFRDGQIIKFWPIRCKRDSKKETFSILPLVSSMVLLPCVLPSYESRTKDSEMARKHEPR SWITLLIYYIKQSWRPHYHYNCRYVITKVLFGWILFYFLQVSKYLTICHPIAHLHQGN
- amino acid sequence ⁇ SEQ ID NO. 241> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 113:
- the following amino acid sequence ⁇ SEQ ID NO. 242> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 114:
- amino acid sequence ⁇ S ⁇ Q ID NO. 243> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 115:
- amino acid sequence ⁇ SEQ ID NO. 244> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 116:
- the following amino acid sequence ⁇ SEQ ID NO. 245> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 117:
- amino acid sequence ⁇ SEQ ID NO. 246> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 118:
- amino acid sequence ⁇ SEQ ID NO. 247> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 119:
- amino acid sequence ⁇ SEQ ID NO. 248> is the predicted amino acid ' sequence derived from the DNA sequence of SEQ ID NO. 120:
- the following amino acid sequence ⁇ SEQ ID NO. 249> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 121:
- the following amino acid sequence ⁇ SEQ ID NO. 250> is a predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 122:
- amino acid sequence ⁇ SEQ ID NO. 251> is a predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 122:
- the following amino acid sequence ⁇ SEQ ID NO. 252> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 123:
- amino acid sequence ⁇ SEQ ID NO. 253> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 124:
- amino acid sequence ⁇ SEQ ID NO. 254> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 125:
- amino acid sequence ⁇ SEQ ID NO. 255> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 126:
- amino acid sequence ⁇ SEQ ID NO. 257> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 128:
- EXAMPLE 2 CLONING OF nGPCR-x cDNAs may be sequenced directly using an AB1377 or ABI373A fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISM Ready Dye-Deoxy Terminator kit with Taq FS polymerase.
- Each ABI cycle sequencing reaction contains about 0.5 ⁇ g of plasmid DNA. Cycle-sequencing is performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 98°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60t for 4 min. Temperature cycles and times are controlled by a Perkin-Elmer 9600 thermocycler.
- Extension products are purified using Centriflex gel filtration (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each reaction product is loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B table top centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples are dried under vacuum for about 40 min and then dissolved in 5 ⁇ l of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples are then heated to 90°C for three min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer.
- a DNA loading solution 83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran
- Sequence analysis is performed by importing ABI373A files into the Sequencher program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp are obtained. Potential sequencing errors are minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers at different locations until all sequencing ambiguities are removed. [000240] To isolate a cDNA clone encoding full length nGPCR, a DNA fragment corresponding to a nucleotide sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128, or a portion thereof, can be used as a probe for hybridization screening of a phage cDNA library.
- the DNA fragment is amplified by the polymerase chain reaction (PCR) method.
- the PCR reaction mixture of 50 ⁇ l contains polymerase mixture (0.2mM dNTPs, lx PCR Buffer and 0.75 ⁇ l Expand High Fidelity Polymerase (Roche Biochemicals)), l ⁇ g of 3206491 plasmid, and 50pmoles of forward primer and 50pmoles of reverse primer.
- the primers are preferably 10 to 25 nucleotides in length and are determined by procedures well known to those skilled in the art.
- Amplification is performed in an Applied Biosystems PE2400 thermocycler, using the following program: 95°C for 15 seconds, 52°C for 30 seconds and 72°C for 90 seconds; repeated for 25 cycles.
- the amplified product is separated from the plasmid by agarose gel electrophoresis, and purified by Qiaquick gel extraction kit (Qiagen).
- a lambda phage library containing cDNAs cloned into lambda ZAPII phage-vector is plated with E. coli XL-1 blue host, on 15 cm LB-agar plates at a density of 50,000 pfu per plate, and grown overnight at 37°C; (plated as described by Sambrooket al, supra).
- Phage plaques are transferred to nylon membranes (Amersham Hybond NJ), denatured for 2 minutes in denaturation solution (0.5 M NaOH, 1.5 M NaCl), renatured for 5 minutes in renaturation solution (1 M Tris pH 7.5, 1.5 M NaCl), and washed briefly in 2xSSC (20x SSC: 3 M NaCl, 0.3 M Na-citrate). Filter membranes are dried and incubated at 80°C for 120 minutes to cross-link the phage DNA to the membranes.
- the membranes are hybridized with a DNA probe prepared as described above.
- a DNA fragment (25ng) is labeled with ⁇ - P-dCTP (NEN) using Rediprime random priming (Amersham Pharmacia Biotech), according to the manufacturer's instructions.
- Labeled DNA is separated from unincorporated nucleotides by S200 spin columns (Amersham Pharmacia Biotech), denatured at 95°C for 5 minutes and kept on ice.
- the DNA-containing membranes (above) are pre-hybridized in 50ml ExpressHyb (Clontech) solution at 68°C for 90 minutes.
- the labeled DNA probe is added to the hybridization solution, and the probe is left to hybridize to the membranes at 68°C for 70 minutes.
- the membranes are washed five times in 2x SSC, 0.1% SDS at 42°C for 5 minutes each, and finally washed 30 minutes in O.lx SSC, 0.2%) SDS.
- Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with an intensifying screen at-80°C for 16 hours.
- One positive colony is isolated from the plates, and re-plated with about 1000 pfu on a 15 cm LB plate. Plating, plaque lift to filters and hybridization are performed as described above.
- cDNA containing plasmids (pBluescript SK-) are rescued from the isolated phages by in vivo excision by culturing XL-1 blue cells co-infected with the isolated phages and with the Excision helper phage, as described by the manufacturer (Stratagene).
- XL-blue cells containing the plasmids are plated on LB plates and grown at 37°C for 16 hours. Colonies (18) from each plate are replated on LB plates and grown. One colony from each plate is stricken onto a nylon filter in an ordered array, and the filter is placed on a LB plate to raise the colonies.
- the filter is then hybridized with a labeled probe as described above. About three positive colonies are selected and grown up in LB medium. Plasmid DNA is isolated from the three clones by Qiagen Midi Kit (Qiagen) according to the manufacturer's instructions. The size of the insert is determined by digesting the plasmid with the restriction enzymes Notl and Sail, which establishes an insert size. The sequence of the entire insert is determined by automated sequencing on both strands of the plasmids.
- EXAMPLE 3 SUBCLONING OF THE CODING REGION OF nGPCR-X VIA PCR
- PCRprimers are designed based on the coding region of nGPCR, corresponding to either end.
- primers are routinely synthesized with a protective run of nucleotides at the 5' end that were not necessarily complementary to the desired target.
- PCR is performed in a 50 ⁇ l reaction containing 34 ⁇ l H 2 O, 5 ⁇ l 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5 ⁇ l 15mM MgS0 , 2 ⁇ l dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 10 mM), 3 ⁇ l genomic phage DNA (0.25 ⁇ g/ ⁇ l), 0.3 ⁇ l Primer 1 (l ⁇ g/ ⁇ l), 0.3 ⁇ l Primer 2 (l ⁇ g/ ⁇ l), 0.4 ⁇ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94°C for 2 minutes; followed by 25 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1.3 minutes.
- 10X TT buffer 140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris
- the DNA band of expected size is excised from the gel, placed in a GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microfuge.
- the eluted DNA is precipitated with ethanol and resuspended in 6 ⁇ l H 2 O for ligation.
- the PCR-amplified DNA fragment containing the coding region is cloned into pCR2.1 using a protocol standard in the art.
- the ligation reaction conssts of 6 ⁇ l of GPCR DNA, l ⁇ l 10X ligation buffer, 2 ⁇ l pCR2.1 (25ng/ ⁇ l, Invitrogen), and l ⁇ l T4 DNA ligase (Invitrogen).
- the reaction mixture is incubated overnight at 14°C and the reaction is then stopped by heating at 65°C for 10 minutes. Two microlitersof the ligation reaction are transformed into One Shot cells (Invitrogen) and plated onto ampicillin plates.
- Plasmid DNA is purified using the Concert Rapid Plasmid Miniprep System (GibcoBRL) and sequenced. Following confirmation of the sequence, a 50 ml culture of LB medium is inoculated with the transformed One Shot cells, cultured, and processed using a Qiagen Plasmid Midi Kit to yield purified pCR-GPCR.
- nGPCR-x in mammals may be investigated by in situ hybridization histochemistry.
- coronal and sagittal rat brain cryosections (20 ⁇ m thick) are prepared using a Reichert-Jung cryostat. Individual sections are thaw-mounted onto silanized, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at-80°C.
- Sections are processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold phosphate-buffered saline (PBS), acetylated using acetic anhydride in triethanolamine buffer, and dehydrated through a series of alcohol washes in 70%, 95%, and 100% alcohol at room temperature. Subsequently, sections are delipidated in chloroform, followed by rehydration through successive exposure to 100%) and 95%) alcohol at room temperature. Microscope slides containing processed cryosections are allowed to air dry prior to hybridization. Other tissues may be assayed in a similar fashion.
- PBS cold phosphate-buffered saline
- a nGPCR-x-specific probe is generated using PCR. Following PCR amplification, the fragment is digested with restriction enzymes and cloned into pBluescript II cleaved with the same enzymes. For production of a probe specific for the sense strand of nGPCR-x, the nGPCR-x clone in pBluescript II is linearized with a suitable restriction enzyme, which provides a substrate for labeled run-off transcripts (i.e., cRNA riboprobes) using the vector-borne T7 promoter and commercially available T7 RNA polymerase.
- a suitable restriction enzyme which provides a substrate for labeled run-off transcripts (i.e., cRNA riboprobes) using the vector-borne T7 promoter and commercially available T7 RNA polymerase.
- a probe specific for the antisense strand of nGPCR-x is also readily prepared using the nGPCR-x clone in pBluescript II by cleaving the recombinant plasmid with a suitable restriction enzyme to generate a linearized substrate for the production of labeled run-off cRNA transcripts using the T3 promoter and cognate polymerase.
- the riboprobes are labeled with [ 35 S]-UTP to yield a specific activity of about 0.40 x 10 cpm/pmol for antisense riboprobes and about 0.65 x 10 6 cpm/pmol for sense- strand riboprobes.
- Each riboprobe is subsequently denatured and added (2 pmol/ml) to hybridization buffer which contained 50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, lX Denhardt's Solution, and 10 mM dithiothreitol.
- hybridization buffer which contained 50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, lX Denhardt's Solution, and 10 mM dithiothreitol.
- Microscope slides containing sequential brain cryosections are independently exposed to 45 ⁇ l of hybridization solution per slide and silanized cover slips are placed over the sections being exposed to hybridization solution. Sections are incubated overnight (15-18 hours) at 52°C to allow hybridization to occur. Equivalent series of cryosections are exposed to sense or antisense nGPCR-x-specific cRNA riboprobe
- coverslips are washed off the slides in IX SSC, followed by RNase A treatment involving the exposure of slides to 20 ⁇ g/ml RNase A in a buffer containing lOmM Tris-HCl (pH 7.4), 0.5M EDTA, and 0.5M NaCl for 45 minutes at 37°C.
- the cryosections are then subjected to three high-stringency washes in 0.1 X SSC at 52°C for 20 minutes each.
- cryosections are dehydrated by consecutive exposure to 70%, 95%, and 100% ammonium acetate in alcohol, followed by air drying and exposure to Kodak BioMaxTM MR-1 film. After 13 days of exposure, the film is developed.
- slides containing tissue that hybridized are coated with Kodak NTB-2 nuclear track emulsion and the slides are stored in the dark for 32 days. The slides are then developed and counterstained with hematoxylin. Emulsion-coated sections are analyzed microscopically to determine the specificity of labeling. The signal is determined to be specific if autoradiographic grains (generated by antisense probe hybridization) are clearly associated with cresyl violate-stained cell bodies. Autoradiographic grains found between cell bodies indicates non-specific binding of the probe.
- nGPCR-x As discussed above, it is well known that GPCRs are expressed in many different tissues and regions, including in the brain. Expression of nGPCR-x in the brain provides an indication that modulators of nGPCR-x activity have utility for treating neurological disorders, including but not limited to, mental disorder, affective disorders, ADHD/ADD (i.e., Attention Deficit- Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Al ⁇ heimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-x may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-x modulators, including nGPCR-x ligands and anti-nGPCR-x antibodies, to treat individuals having such disease states is intended as an aspect of the invention.
- the RapidScan Expression Panel is comprised of first-strand cDNAs from various human tissues and brain regions that are serially diluted over a 4-log range and arrayed into a multi-well PCR plate.
- Human tissues in the array may include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, and fetal liver.
- PCR is performed in a 50 ⁇ l reaction containing 34 ⁇ l H 2 O, 5 ⁇ l 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5 ⁇ l 15mM MgSO 4 , 2 ⁇ l dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at lOmM), 0.3 ⁇ l forward primer (l ⁇ g/ ⁇ l), 0.3 ⁇ l reverse primer (l ⁇ g/ ⁇ l), 0.4 ⁇ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction mixture is added to each well of the PCR plate.
- 10X TT buffer 140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4
- 5 ⁇ l 15mM MgSO 4 2 ⁇ l dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at
- the plate is placed in a MJ Research PTC100 thermocycler, and is then exposed to the following cycling parameters: Pre-soak 94°C for 3 min; denaturation at 94°C for 30 seconds; annealing at primer 57°C for 45 seconds, extension 72°C for 2 minutes; for 35 cycles. PCR productions are then separated and analyzed by electrophoresis on a 1.2% agarose gel stained with ethidium bromide.
- the 4-log dilution range of cDNA deposited on the plate ensures that the amplification reaction is within the linear range and, hence, facilitates semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.
- Northern blots are performed to examine the expression of nGPCR-x mRNA.
- the sense orientation oligonucleotide and the antisense-orientation oligonucleotide, described above, are used as primers to amplify a portion of the GPCR-x cDNA sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128.
- the probe is labeled with - 32 P-dCTP by RediprimeTM DNA labeling system
- nGPCR-x protein a nGPCR-x-encoding polynucleotide is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques.
- the nGPCR-x-encoding sequence described in Example 1 is subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected into Chinese Hamster Ovary (CHO) cells using the transfection reagentFuGENE ⁇ TM (Boehringer-Mannheim) and the transfection protocol provided in the product insert.
- Other eukaryotic cell lines including human embryonic kidney (HEK-293) and COS cells, are suitable as well.
- nGPCR-x may be purified from the cells using standard chromatographic techniques. To facilitate purification, antisera is raised against one or more synthetic peptide sequences that correspond to portions of the nGPCR-x amino acid sequence, and the antisera is used to affinity purify nGPCR-x.
- the nGPCR-x also may be expressed in-frame with a tag sequence (e.g., polyhistidine, hemagluttinin, FLAG) to facilitate purification.
- tag sequence e.g., polyhistidine, hemagluttinin, FLAG
- nGPCR-x For expression of nGPCR-x in mammalian cells HEK293 (transformed human, primary embryonic kidney cells), a plasmid bearing the relevant nGPCR-x coding sequence is prepared, using vector pSecTag2A (Invitrogen).
- Vector pSecTag2A contains the murine IgK chain leader sequence for secretion, the c-myc epitope for detection of the recombinant protein with the anti- myc antibody, a C-terminal polyhistidine for purification with nickel chelate chromatography, and a Zeocin resistant gene for selection of stable transfectants.
- the forward primer for amplification of this GPCR cDNA is determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce the Hindlll cloning site and nucleotides matching the GPCR sequence.
- the reverse primer is also determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce an Xliol restriction site for cloning and nucleotides corresponding to the reverse complement of the nGPCR-x sequence.
- the PCR conditions are 55°C as the annealing temperature.
- the PCR product is gel purified and cloned into the Hindlll-Xhol sites of the vector.
- the DNA is purified using Qiagen chromatography columns and transfected into HEK-
- 293 cells using DOTAPTM transfection media (Boehringer Mannheim, Indianapolis, IN). Transiently transfected cells are tested for expression after 24 hours of transfection, using western blots probed with anti-His and anti-nGPCR-x peptide antibodies. Permanently transfected cells are selected with Zeocin and propagated. Production of the recombinant protein is detected from both cells and media by western blots probed with anti-His, anti-Myc or anti-GPCR peptide antibodies.
- a polynucleotide molecule .having a sequence selected from the group- consisting of SEQ ID NO:l to SEQ ID NO: 128 can be cloned into vector p3-CI.
- This vector is a pUC18-derived plasmid that contains the HCMV (human cytomegalovirus) promoter-intron located upstream from the bGH (bovine growth hormone) polyadenylation sequence and a multiple cloning site.
- the plasmid contains the dhrf (dihydrofolate reductase) gene which provides selection in the presence of the drug methotrexane (MTX) for selection of stable transformants.
- HCMV human cytomegalovirus
- bGH bovine growth hormone
- the forward primer is determined by routine procedures and preferably contains a 5' extension which introduces an Xbal restriction site for cloning, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128.
- the reverse primer is also determined by routine procedures and preferably contains 5'- extension of nucleotides which introduces a S t/cloning site followed by nucleotides which correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 128.
- the PCR consists of an initial denaturation step of 5 min at 95 > C 30 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 58°C and 30 sec extension at 72°C, followed by 5 min extension at 72°C.
- the PCR product is gel purified and ligated into theXbal and Sail sites of vector p3-CI. This construct is transformed into E. coli cells for amplification and DNA purification.
- the DNA is purified with Qiagen chromatography columns and transfected into COS 7 cells using LipofectamineTM reagent from BRL, following the manufacturer's protocols. Forty-eight and 72 hours after transfection, the media and the cells are tested for recombinant protein expression.
- nGPCR-x expressed from a COS cell culture can be purified by concentrating the cell- growth media to about 10 mg of protein/ml, and purifying the protein by, for example, chromatography. Purified nGPCR-x is concentrated to 0.5 mg/ml in an Amicon concentrator fitted with a YM-10 membrane and stored at -80°C.
- nGPCR-x for expression of nGPCR-x in a baculovirus system, a polynucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128 can be amplified by PCR.
- the forward primer is determined by routine procedures and preferably contains a 5' extension which adds the Ndel cloning site, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128.
- the reverse primer is also determined by routine procedures and preferably contains a 5' extension which introduces the Kpnl cloning site, followed by nucleotides which correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128.
- the PCR product is gel purified, digested with Ndel andKpnl, and cloned into the corresponding sites of vector pACHTL-A (Pharmingen, San Diego, CA).
- the pAcHTL expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV), and a 6XHis tag upstream from the multiple cloning site.
- a protein kinase site for phosphorylation and a thrombin site for excision of the recombinant protein precede the multiple cloning site is also present.
- baculovirus vectors could be used in place of pAcHTL-A, such as pAc373, pVL941 and pAcIMl.
- Other suitable vectors for the expression of GPCR polypeptides can be used, provided that the vector construct includes appropriately located signals for transcription, translation, and trafficking, such as an in-frame AUG and a signal peptide, as required.
- Such vectors are described in Luckow et al, Virology 170:31-39, among others.
- the virus is grown and isolated using standard baculovirus expression methods, such as those described in Summers et al (A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987)).
- pAcHLT-A containing nGPCR-x gene is introduced into baculovirus using the "BaculoGoldTM transfection kit (Pharmingen, San Diego, CA) using methods established by the manufacturer. Individual virus isolates are analyzed for protein production by radiolabeling infected cells with 35 S-methionine at 24 hours post infection. Infected cells are harvested at 48 hours post infection, and the labeled proteins are visualized by SDS-PAGE. Viruses exhibiting high expression levels can be isolated and used for scaled up expression.
- nGPCR-x polypeptide for expression in a Sf9 cells, a polynucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:l to SEQ ID NO: 128 can be amplified by PCR using the primers and methods described above for baculovirus expression.
- the nGPCR-x cDNA is cloned into vector pAcHLT-A (Pharmingen) for expression in Sf9 insect.
- the insert is cloned into the Ndeland Kpnl sites, after elimination of an internal Ndel site (using the same primers described above for expression in baculovirus).
- DNA is purified with Qiagen chromatography columns and expressed in Sf9 cells. Preliminary Western blot experiments from non-purified plaques are tested for the presence of the recombinant
- the interaction trap/two-hybrid library screening method can be used. This assay was first described in Fields et al, Nature, 1989, 340, 245, which is incorporated herein by reference in its entirety. A protocol is published in Current Protocols in Molecular Biology 1999, John Wiley & Sons, NY, and Ausubel, F. M et al. 1992, Short protocols in molecular biology, Fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety. Kits are available from Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3).
- a fusion of the nucleotide sequences encoding all or partial nGPCR-x and the yeast transcription factor GAL4 DNA-binding domain is constructed in an appropriate plasmid (i.e., pGBKT7) using standard subcloning techniques.
- a GAL4 active domain (AD) fusion library is constructed in a second plasmid (i.e., pGADT7) from cDNA of potential GPCR-binding proteins (for protocols on forming cDNA libraries, see Sambrooket al. 1989, Molecular cloning: a laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY), which is incorporated herein by reference in its entirety.
- the DNA- BD/nGPCR-x fusion construct is verified by sequencing, and tested for autonomous reporter gene activation and cell toxicity, both of which would prevent a successful two-hybrid analysis. Similar controls are performed with the AD/library fusion construct to ensure expression in host cells and lack of transcriptional activity.
- Yeast cells are transformed (ca 105 transformants/mg DNA) with both the nGPCR-x and library fusion plasmids according to standard procedures (Ausubel et al, 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley- interscience, NY, which is incorporated herein by reference in its entirety).
- yeast plasmid reporter genes i.e., lacZ, HIS3, ADE2, LEU2
- Yeast cells are plated on nutrientdeficient media to screen for expression of reporter genes. Colonies are dually assayed for ⁇ - galactosidase activity upon growth in Xgal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside) supplemented media (filter assay for ⁇ -galactosidase activity is described in Breeden et al, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, which is incorporated herein by reference in its entirety).
- EXAMPLE 9 MOBILITY SHIFT DNA-BINDING ASSAY USING GEL ELECTROPHORESIS
- a gel electrophoresis mobility shift assay can rapidly detect specific protein-DNA interactions. Protocols are widely available in such manuals as Sambrook et al. 1989, Molecular cloning: a laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY and Ausubel, F. M. et al, 1992, Short Protocols in Molecular Biology, fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety.
- Probe DNA ( ⁇ 300 bp) is obtained from synthetic oligonucleotides, restriction endonuclease fragments, or PCR fragments and end-labeled with 32 P.
- An aliquot of purified nGPCR-x (ca. 15 ⁇ g) or crude nGPCR-x extract (ca. 15 ng) is incubated at constant temperature (in the range 22-37 C) for at least 30 minutes in 10-15 ⁇ l of buffer (i.e. TAE or TBE, pH 8.0- 8.5) containing radiolabeled probe DNA, nonspecific carrier DNA (ca. 1 ⁇ g), BSA (300 ⁇ g/ml), and 10% (v/v) glycerol.
- the reaction mixture is then loaded onto a polyacrylamide gel and run at 30-35 mA until good separation of free probe DNA from protein-DNA complexes occurs.
- the gel is then dried and bands corresponding to free DNA and protein-DNA complexes are detected by autoradiography.
- Standard techniques are employed to generate polyclonal or monoclonal antibodies to the nGPCR-x receptor, and to generate useful antigen-binding fragments thereof or variants thereof, including "humanized” variants.
- Such protocols can be found, for example, in Sambrook et al. (1989) and Harlow et al (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988).
- recombinant nGPCR- x polypeptides or cells or cell membranes containing such polypeptides
- one or more peptides having amino acid sequences corresponding to an immunogenic portion of nGPCR-x are used as antigen.
- Peptides corresponding to extracellular portions of nGPCR-x, especially hydrophilic extracellular portions, are preferred.
- the antigen may be mixed with an adjuvant or linked to a hapten to increase antibody production.
- nGPCR-x or a synthetic fragment thereof is used to immunize a mouse for generation of monoclonal antibodies (or larger mammal, such as a rabbit, for polyclonal antibodies).
- peptides are conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's recommendations.
- the antigen is emulsified with Freund's Complete Adjuvant and injected subcutaneously.
- additional aliquots of nGPCR-x antigen are emulsified with Freund's Incomplete Adjuvant and injected subcutaneously.
- a serum sample is taken from the immunized mice and assayed bywestern blot to confirm the presence of antibodies that immunoreact with nGPCR-x.
- Serum from the immunized animals may be used as polyclonal antisera or used to isolate polyclonal antibodies that recognize nGPCR-x. Alternatively, the mice are sacrificed and their spleen removed for generation of monoclonal antibodies.
- RPMI 1640 single cell suspensions are formed by grinding the spleens in serum-free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin (RPMI) (Gibco, Canada).
- the cell suspensions are filtered and washed by centrifugation and resuspended in serum-free RPMI.
- Thymocytes taken from three naive Balb/c mice are prepared in a similar manner and used as a Feeder Layer.
- NS-1 myeloma cells kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, are centrifuged and washed a. well.
- FBS fetal bovine serum
- NS-1 cells and centrifuged, and the supernatant is aspirated.
- the cell pellet is dislodged by tapping the tube, and 2 ml of 37°C PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer- Mannheim) is stirred into the pellet, followed by the addition of serum-free RPMI.
- the cells are centrifuged, resuspended in RPMI containing 15% FBS, 100 ⁇ M sodium hypoxanthine, 0.4 ⁇ M aminopterin, 16 ⁇ Mthymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and 1.5 x 10 6 thymocytes/ml, and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York).
- nGPCR-x-neutralizing antibodies comprise one class of therapeutics useful as nGPCR-x antagonists. Following are protocols to improve the utility of anti-nGPCR-x monoclonal antibodies as therapeutics in humans by "humanizing" the monoclonal antibodies to improve their serum half-life and render them less immunogenic in human hosts (i.e., to prevent human antibody response to non-human anti-nGPCR-x antibodies).
- a level of humanization is achieved by generating chimeric antibodies comprising the variable domains of non-human antibody proteins of interest with the constant domains of human antibody molecules.
- the variable domains of nGPCR-x-neutralizing anti-nGPCR-x antibodies are cloned from the genomic DNA of a B-cell hybridoma or from cDNA generated from mRNA isolated from the hybridoma of interest.
- the V region gene fragments are linked to exons encoding human antibody constant domains, and the resultant construct is expressed in suitable mammalian host cells (e.g., myeloma or CHO cells). )
- variable region gene fragments that encode antigen-binding complementarity determining regions (“CDR") of the non-human monoclonal antibody genes are cloned into human antibody sequences.
- CDR complementarity determining regions
- the ⁇ -sheet framework of the human antibody surrounding the CDR3 regions also is modified to more closely mirror the three dimensional structure of the antigen-binding domain of the original monoclonal antibody.
- the surface of a non-human monoclonal antibody of interest is humanized by altering selected surface residues of the non-human antibody, e.g., by site-directed mutagenesis, while retaining all of the interior and contacting residues of the non-human antibody. See Padlan, Molecular Immunol., 28(4/5):489-98 (1991).
- nGPCR-x-neutralizing anti-nGPCR-x monoclonal antibodies and the hybridomas that produce them to generate humanized nGPCR- x-neutralizing antibodies useful as therapeutics to treat or palliate conditions wherein nGPCR-x expression or ligand-mediated nGPCR-x signaling is detrimental.
- Human nGPCR-x-Neutralizing Antibodies are generated by phage display techniques such as those described in Aujame et al, Human Antibodies 8(4):155-168 (1997); Hoogenboom, TIBTECH 15:62-70 (1997); and Rader et al, Curr. Opin. Biotechnol. 8:503-508 (1997), all of which are incorporated by reference.
- antibody variable regions in the form of Fab fragments or linked single chain Fv fragments are fused to the amino terminus of filamentous phage minor coat protein pill.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001249228A AU2001249228A1 (en) | 2000-03-16 | 2001-03-16 | Human g protein-coupled receptors |
Applications Claiming Priority (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18996000P | 2000-03-16 | 2000-03-16 | |
US18991700P | 2000-03-16 | 2000-03-16 | |
US18991800P | 2000-03-16 | 2000-03-16 | |
US18990700P | 2000-03-16 | 2000-03-16 | |
US18978300P | 2000-03-16 | 2000-03-16 | |
US60/189,907 | 2000-03-16 | ||
US60/187,783 | 2000-03-16 | ||
US60/189,917 | 2000-03-16 | ||
US60/189,918 | 2000-03-16 | ||
US60/189,960 | 2000-03-16 | ||
US19223400P | 2000-03-27 | 2000-03-27 | |
US60/192,234 | 2000-03-27 | ||
US19293300P | 2000-03-29 | 2000-03-29 | |
US19294500P | 2000-03-29 | 2000-03-29 | |
US19292300P | 2000-03-29 | 2000-03-29 | |
US19215500P | 2000-03-29 | 2000-03-29 | |
US19291600P | 2000-03-29 | 2000-03-29 | |
US19283000P | 2000-03-29 | 2000-03-29 | |
US60/192,945 | 2000-03-29 | ||
US60/192,933 | 2000-03-29 | ||
US60/192,830 | 2000-03-29 | ||
US60/192,923 | 2000-03-29 | ||
US60/192,155 | 2000-03-29 | ||
US60/192,916 | 2000-03-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001068858A2 true WO2001068858A2 (fr) | 2001-09-20 |
WO2001068858A3 WO2001068858A3 (fr) | 2002-08-29 |
WO2001068858A8 WO2001068858A8 (fr) | 2005-03-24 |
Family
ID=34317883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/008456 WO2001068858A2 (fr) | 2000-03-16 | 2001-03-16 | Nouveaux recepteurs couples a la proteine g |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001068858A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001088127A2 (fr) * | 2000-05-18 | 2001-11-22 | Bayer Aktiengesellschaft | Régulation du récepteur couplé à la protéine g analogue à l'hormone folliculo-stimulante humaine |
WO2002014489A2 (fr) * | 2000-08-10 | 2002-02-21 | Amgen, Inc. | Molecules du recepteur 8 couple a la protenie g contenant des repetitions riches en leucines, et utilisations associees |
WO2002103006A1 (fr) * | 2001-06-18 | 2002-12-27 | National Institute Of Advanced Industrial Science And Technology | Recepteurs couples a la proteine de liaison a la guanosine triphosphate |
US8796441B2 (en) | 2005-04-13 | 2014-08-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human sweet and umami taste receptor variants |
CN113929766A (zh) * | 2015-02-18 | 2022-01-14 | 麻省理工学院 | 水溶性跨膜蛋白及其制备和使用方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055732A1 (fr) * | 1998-04-24 | 1999-11-04 | Astrazeneca Ab | Nouveau recepteur couple a la proteine g |
-
2001
- 2001-03-16 WO PCT/US2001/008456 patent/WO2001068858A2/fr active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055732A1 (fr) * | 1998-04-24 | 1999-11-04 | Astrazeneca Ab | Nouveau recepteur couple a la proteine g |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL [Online] accession: AC009879, 7 September 1999 (1999-09-07) BIRREN B ET AL: "Homo sapiens clone RP11-346I3, *** SEQUENCING IN PROGRESS ***, 6 unordered pieces." XP002188096 * |
HERZOG H ET AL: "CLONED HUMAN NEUROPEPTIDE Y RECEPTOR COUPLES TO TWO DIFFERENT SECOND MESSENGER SYSTEMS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, no. 13, 1992, pages 5794-5798, XP002180040 ISSN: 0027-8424 * |
SAKURAI T ET AL: "Orexins and orexin receptors: A family of hypothalamic neuropeptides and G Protein-coupled receptors that regulate feeding behaviour" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 92, 20 February 1998 (1998-02-20), pages 573-585, XP002105412 ISSN: 0092-8674 cited in the application * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001088127A2 (fr) * | 2000-05-18 | 2001-11-22 | Bayer Aktiengesellschaft | Régulation du récepteur couplé à la protéine g analogue à l'hormone folliculo-stimulante humaine |
WO2001088127A3 (fr) * | 2000-05-18 | 2002-09-19 | Bayer Ag | Régulation du récepteur couplé à la protéine g analogue à l'hormone folliculo-stimulante humaine |
WO2002014489A2 (fr) * | 2000-08-10 | 2002-02-21 | Amgen, Inc. | Molecules du recepteur 8 couple a la protenie g contenant des repetitions riches en leucines, et utilisations associees |
WO2002014489A3 (fr) * | 2000-08-10 | 2002-07-25 | Amgen Inc | Molecules du recepteur 8 couple a la protenie g contenant des repetitions riches en leucines, et utilisations associees |
WO2002103006A1 (fr) * | 2001-06-18 | 2002-12-27 | National Institute Of Advanced Industrial Science And Technology | Recepteurs couples a la proteine de liaison a la guanosine triphosphate |
US8796441B2 (en) | 2005-04-13 | 2014-08-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human sweet and umami taste receptor variants |
CN113929766A (zh) * | 2015-02-18 | 2022-01-14 | 麻省理工学院 | 水溶性跨膜蛋白及其制备和使用方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2001068858A3 (fr) | 2002-08-29 |
WO2001068858A8 (fr) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050112660A1 (en) | Novel G protein-coupled receptors | |
US20020062013A1 (en) | Novel G protein-coupled receptors | |
WO2001066750A2 (fr) | Nouveaux recepteurs couples a la proteine g | |
WO2002064789A1 (fr) | Recepteur couple aux proteines | |
US20020015998A1 (en) | Novel G protein-coupled receptors | |
WO2001068858A2 (fr) | Nouveaux recepteurs couples a la proteine g | |
WO2001083553A2 (fr) | Nouveaux recepteurs couples a la proteine g | |
WO2001062924A2 (fr) | Nouveaux recepteurs couples a une proteine g | |
US20030170779A1 (en) | Novel G protein-coupled receptors | |
US20050214790A1 (en) | Novel G protein-coupled receptors | |
US20050069976A1 (en) | Protein-coupled receptor | |
US20020137132A1 (en) | Novel G protein-coupled receptors | |
US20020052021A1 (en) | Novel G protein-coupled receptors | |
US20040105846A1 (en) | Polynucleotides encoding G protein-coupled receptors | |
US20030032019A1 (en) | Novel G protein-coupled receptors | |
US20030023992A1 (en) | Novel G protein-coupled receptors | |
US20030175857A1 (en) | Novel G protein-coupled receptor | |
US20020198368A1 (en) | Novel G protein-coupled receptors | |
WO2001062798A2 (fr) | Nouveaux recepteurs couples a la proteine g | |
WO2001066751A2 (fr) | Nouveaux recepteurs couples aux proteines g | |
EP1686135A1 (fr) | Récepteurs couplés à la protéine G |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 38/2001 UNDER (30) REPLACE "60/192,234, 29 MARCH 2000 (29.03.2000), US" BY "60/192,234, 27 MARCH 2000 (27.03.2000), US" |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |